Stable sustained release therapeutic compositions in aprotic polar solvents and methods for making same

Abstract

The present invention relates to the use of an aprotic polar solvent and an ionization stabilizer to prepare a storage-stable sustained-release therapeutic formulation by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system, which can then be administered to patients suffering from or susceptible to various physical conditions or disorders, particularly hypoglycemia. In certain embodiments, the present invention relates to a formulation containing one or more therapeutic agents, as well as a method for making such a formulation, which comprises at least one therapeutic agent dissolved in an aprotic polar solvent, such as DMSO, containing at least one ionization stabilizer excipient (suitably an inorganic acid) and at least one sustained-release modifier (suitably a divalent cation-donating compound, such as a zinc salt and / or a polymer, such as PLGA), at concentrations sufficient to provide physical and chemical stability to the therapeutic agent and to produce a formulation that provides sustained release of the therapeutic agent into the bloodstream of an animal to which the formulation is administered. The present invention also relates to methods for producing such storage-stable sustained-release therapeutic formulations and methods for treating, preventing, and diagnosing certain physical conditions and disorders, particularly hypoglycemia, by administering such storage-stable sustained-release therapeutic formulations to a patient.

Description

[Technical Field]

[0001] CROSS-REFERENCE AND INCORPORATION-BY-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 044,973, filed June 26, 2020, the disclosure of which is incorporated herein by reference in its entirety.

[0002] A. Field of the Invention The present invention is in the fields of medicine and pharmacy. Certain aspects generally relate to aprotic solvent formulations for sustained release therapy with enhanced storage stability, which contain one or more active pharmaceutical ingredients and can be used as therapeutic preparations for treating, preventing, and / or diagnosing diseases, disorders, and medical conditions in mammals, particularly humans. In particular, the present invention relates to the use of aprotic polar solvents and at least one stabilizer to prepare stable sustained release therapeutic formulations by dissolving a therapeutic agent (active pharmaceutical ingredient), at least one ionization stabilizer, and at least one sustained release modifier in an aprotic polar solvent system, which formulation can then be used with various devices for administering the formulation. The present invention also relates to methods for preparing and using such stable sustained release formulations. [Background technology]

[0003] B. Description of Related Technical Fields Hypoglycemia, or low blood sugar, is a major concern for people with diabetes. In healthy individuals, glucagon release is the body's primary defense against insulin-induced hypoglycemia. In healthy individuals, glucagon counterbalances the effects of insulin on glucose metabolism by stimulating glycogenolysis and gluconeogenesis, maintaining blood glucose within the normoglycemic range.

[0004] As the primary counterregulatory hormone to insulin, glucagon is used therapeutically as a first-line treatment for severe hypoglycemia in diabetic patients. However, its use is limited by its poor solubility and stability in water, which results in time-consuming reconstitution and preparation steps before administration to hypoglycemic patients.

[0005] Gvoke® (glucagon injection) (Xeris Pharmaceuticals, Chicago, IL) is the first ready-to-use, room-temperature, liquid, stable glucagon approved for the treatment of severe hypoglycemia in pediatric and adult diabetic patients aged 2 years and older. (1, 2) This commercial, FDA-approved composition contains therapeutic levels of glucagon in an aprotic polar solvent system (dimethyl sulfoxide (DMSO)) and provides a storage-stable, immediate-release rescue formulation suitable for the treatment and prevention of severe hypoglycemia in patients with or susceptible to it.

[0006] Parenteral formulations, such as Gvoke (glucagon injection), prepared in aprotic polar solvent systems (e.g., DMSO-based solvent systems) offer the benefit of improved drug molecule stability due to the absence of aqueous degradation pathways. These pathways, including hydrolysis, deamidation, and aspartic acid isomerization, are known to be significant contributors to the instability of peptides and proteins in water-based formulations. Furthermore, hydrolysis is also known to promote the chemical instability of small molecule drugs. Previous studies have demonstrated improved stability of such formulations of other therapeutic peptides and small molecules relative to aqueous solutions containing the same active pharmaceutical ingredients (see, for example, U.S. Patent Nos. 9,339,545 and 10,485,850, the disclosures of which are incorporated herein by reference in their entireties).

[0007] The availability of liquid stable glucagon opens up the possibility of using glucagon beyond the relief of severe hypoglycemia. In particular, low-dose sustained-release (SR) glucagon formulations could expand the treatment options available for conditions such as hypoglycemia unawareness, nocturnal hypoglycemia, exercise-induced hypoglycemia, and congenital hyperinsulinism. For such conditions, patients often undergo multiple rounds of oral carbohydrate ingestion to avoid severe hypoglycemic events, which can lead to sudden hyperglycemia. Treatment with stable SR glucagon formulations could provide a more precise therapeutic option for preventing and treating hypoglycemia, thereby avoiding additional calorie consumption and the resulting hyperglycemia (see, e.g., Haymond, M. et al., Diabetes Care 39: 466-468 (2016)), and help minimize any potential symptoms (e.g., nausea, hyperglycemia) associated with supratherapeutic glucagon levels. The development of stable SR formulations of other therapeutic peptides and small molecules may similarly provide more flexible options for patients suffering from or susceptible to a variety of other disorders and conditions that are suitably treated and / or prevented by administration of such formulations.

[0008] Thus, there remains a need for a formulation platform that combines the stability and solubility offered by aprotic polar solvent systems while also providing the flexibility and enhanced physiological control offered by sustained release therapeutic formulations. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] U.S. Patent No. 9,339,545 [Patent Document 2] U.S. Patent No. 10,485,850 [Non-patent literature]

[0010] [Non-Patent Document 1] Haymond, M. et al., Diabetes Care 39: 466-468 (2016) Summary of the Invention

[0011] Brief Summary of the Invention Embodiments described herein provide storage-stable sustained-release (SR) compositions (formulations) comprising one or more therapeutically active ingredients (e.g., one or more active pharmaceutical ingredients), suitably therapeutic peptides or small molecules. In other embodiments, the invention provides methods of making such storage-stable SR therapeutic formulations. In further embodiments, the invention provides methods of using the storage-stable SR therapeutic formulations of the invention in methods of treating, preventing, and / or diagnosing specific diseases, physical disorders, or conditions in animals, including vertebrates and humans, suffering from or susceptible to such diseases, physical disorders, or conditions.

[0012] In certain exemplary embodiments, the present invention provides storage-stable SR glucagon formulations useful in treating and preventing hypoglycemia, particularly severe hypoglycemia, and as adjuncts to certain diagnostic procedures. Such formulations utilize the same non-aqueous formulation technology as the currently available immediate-release glucagon rescue product (Gvoke®; Xeris Pharmaceuticals, Chicago, IL) to address the stability and solubility challenges of using aqueous glucagon. However, in the present invention, the SR glucagon formulations are prepared by further stabilizing glucagon in a solution containing one or more cation-donating compounds, suitably divalent zinc-containing compounds, e.g., zinc salts, to reduce the water solubility of glucagon while maintaining drug stability. Such storage-stable SR glucagon formulations of the present invention are clear, ready-to-use, non-aqueous solutions prior to injection. When administered subcutaneously, zinc-stabilized glucagon forms a depot due to its poor solubility under physiological conditions, facilitating the gradual release of glucagon into the bloodstream.

[0013] Thus, in certain embodiments, the present invention provides a sustained-release therapeutic formulation comprising (a) at least one therapeutic agent, (b) at least one ionization-stabilizing excipient, (c) at least one sustained-release modifier, and (d) an aprotic polar solvent, wherein the formulation is shelf-stable for at least six months at ambient temperature (e.g., 20°C to 25°C) and, upon administration to a patient, results in therapeutic levels of the therapeutic agent in the patient's blood for a longer period of time than an immediate-release formulation containing the same therapeutic agent. In certain such embodiments, the therapeutic agent is a peptide. Peptides suitable for use in the storage-stable SR formulations of the present invention include, but are not limited to, glucagon peptides, glucagon analogs, glucagon mimetics, or salts thereof. In other embodiments, the therapeutic agent is a small molecule, which may include any small molecule therapeutic agent, particularly those that are negatively charged at physiological pH in humans and other animals. Examples of such small molecule therapeutic agents include, but are not limited to, levothyroxine, sumatriptan, ketorolac, and ondansetron.

[0014] At least one ionization stabilizing excipient may be dissolved in the aprotic solvent in an amount that stabilizes the ionization of the therapeutic agent. In certain aspects, the ionization stabilizing excipient is at a concentration of 0.01 mM to less than 200 mM. The ionization stabilizing excipient may be, but is not limited to, an inorganic acid. In certain embodiments, the inorganic acid may be selected from hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid. The ionization stabilizing excipient may also be an organic acid (an acid having a carboxylic acid -COOH functional group). Non-limiting examples of organic acids include acetic acid, citric acid, and amino acids. In certain aspects, the aprotic solvent is DMSO. In certain aspects, the ionization stabilizing excipient is an inorganic acid and the aprotic solvent is DMSO.

[0015] In certain embodiments, the sustained-release modifier is a divalent cation-donating compound, particularly a zinc-containing compound, such as a zinc salt. Zinc salts suitable for use in this aspect of the invention include, but are not limited to, zinc acetate, zinc chloride, and zinc sulfate.

[0016] In certain embodiments, the present invention provides a storage-stable SR formulation, wherein the therapeutic agent is glucagon, the ionizable stabilizing excipient is an inorganic acid, the sustained-release modifier is a zinc salt, and the aprotic solvent is DMSO.

[0017] In other embodiments, the present invention provides methods for treating, ameliorating, or preventing a disease, physical condition, or disorder in a patient, e.g., a vertebrate or human, suffering from or susceptible to such disease, physical condition, or condition. Suitable such methods according to certain aspects of the present invention comprise introducing to a patient in need thereof an effective amount of a storage-stable SR formulation of the present invention in a manner suitable for promoting sustained release of the therapeutic compound from the formulation into the patient's bloodstream. In certain such embodiments, the formulation is introduced to the subject via parenteral administration, e.g., via injection (which may be subcutaneous, intradermal, or intramuscular injection) or infusion (which may be intravenous or achieved by pump infusion, e.g., continuous or bolus pump infusion, or a combination thereof). In certain aspects, the present invention provides methods for treating or preventing hypoglycemia in a human by administering to the human a storage-stable SR glucagon formulation of the present invention.

[0018] In a further aspect, the present invention provides a method for producing a storage-stable sustained-release therapeutic formulation, the method comprising mixing at least one ionization-stabilizing excipient, at least one sustained-release modifier, an aprotic polar solvent, and at least one therapeutic agent, thereby forming a storage-stable therapeutic formulation that, when administered to a patient, results in therapeutic levels of the therapeutic agent in the patient's blood for a longer period of time than an immediate-release formulation containing the same therapeutic agent. In a suitable such aspect, the therapeutic agent is a peptide, particularly a glucagon peptide, a glucagon analog, a glucagon mimetic, or a salt thereof, the aprotic solvent is DMSO or deoxygenated DMSO, the ionization-stabilizing excipient is an inorganic acid, and the sustained-release modifier is a cation-containing compound, suitably a zinc-containing compound, such as a zinc salt, including, but not limited to, zinc sulfate, zinc chloride, and zinc acetate.

[0019] In a further aspect, the present invention provides methods for diagnosing a disease or physical disorder in a human patient by introducing an effective amount of one of the storage-stable SR formulations of the present invention as an adjunct to a diagnostic test to a patient suffering from, susceptible to, or suspected of suffering from or susceptible to a disease or disorder, and performing the diagnostic test on the patient. Suitable formulations useful in this aspect of the present invention include those described elsewhere herein, particularly the storage-stable SR glucagon formulations of the present invention. Such diagnostic methods can be used to diagnose a variety of diseases, physical disorders, and physical conditions, including, but not limited to, Alzheimer's disease, growth hormone deficiency, and gastrointestinal disorders. In aspects where the method is used to diagnose a gastrointestinal disorder, the diagnostic test is suitably a radiological examination of the patient's gastrointestinal tract. In practicing these diagnostic methods of the present invention, the storage-stable SR therapeutic formulations can be introduced into the patient by any parenteral route, particularly orally, intragastrically, intravenously, intramuscularly, or intradermally.

[0020] To produce the storage-stable SR therapeutic formulations of the present invention, at least one ionization-stabilizing excipient can be dissolved in an aprotic solvent in an amount sufficient to stabilize the ionization of the therapeutic agent. Suitable such ionization-stabilizing excipients (including, but not limited to, inorganic acids) and desired concentrations for inclusion in the formulations of the present invention include those described herein above.

[0021] To prepare the storage-stable SR therapeutic formulations of the present invention, at least one sustained-release modifier can be dissolved in an aprotic solvent in an amount sufficient to prolong the release kinetics of a therapeutic compound into the bloodstream of an animal, e.g., a vertebrate or human, when the formulation is introduced into the animal, compared to the release kinetics of an immediate-release formulation of the same therapeutic compound without the sustained-release modifier. In certain aspects, the sustained-release modifier is present at a concentration of about 0.1 mM to about 100 mM, suitably about 0.5 mM to about 50 mM, and about 1 mM to about 25 mM. The sustained-release modifier can be, but is not limited to, a divalent cation-donating compound, such as a divalent zinc-containing compound, including, but not limited to, zinc sulfate, zinc chloride, and zinc acetate. Zinc sulfate and zinc chloride are particularly preferred in certain embodiments. In certain aspects, the sustained-release modifier is a zinc salt, e.g., zinc sulfate, zinc chloride, or zinc acetate, and the aprotic solvent is DMSO.

[0022] The formulation may further comprise less than 10, 5, or 3% w / v of a preservative, hi certain aspects, the preservative is benzyl alcohol.

[0023] The formulation may further comprise less than 10, 5, or 3% w / v of one or more disaccharides. In certain such aspects, the disaccharide is about 5.5% w / v of trehalose dihydrate.

[0024] The formulation may further comprise less than 10, 5, or 3% w / v of one or more sugar alcohols. In certain such aspects, the sugar alcohol is about 2.9% (w / v) mannitol.

[0025] In certain embodiments, the formulation may have a freezing point of about 10°C or less, e.g., about 10°C, about 5°C, about 0°C, or less than about 0°C, e.g., less than -20°C, or between -50°C and -70°C.

[0026] In certain embodiments, the formulation comprises a therapeutically effective amount of a therapeutic peptide or small molecule. In certain such aspects, the formulation comprises glucagon at a concentration (w / w) of about 0.5 mg / mL to about 20 mg / mL, suitably about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 2.5 mg / mL, about 5 mg / mL, about 10 mg / mL, about 15 mg / mL, or about 20 mg / mL. In other aspects, the concentrations of zinc ions and glucagon are adjusted to provide a zinc:glucagon ratio in the formulation of about 1:1 to about 20:1, suitably about 1:1, about 2:1, about 4:1, about 5:1, about 8:1, about 10:1, about 12:1, about 15:1, about 16:1, or about 20:1.

[0027] Certain embodiments relate to methods of treating hypoglycemia by administering to a subject in need thereof an effective amount of a formulation described herein. In certain aspects, the formulation is administered by infusion. In certain aspects, administration is by infusion through a pump that can be connected in series with an infusion set. The infusion can be continuous and / or bolus pump infusion.

[0028] Certain embodiments relate to methods for stably formulating sustained-release therapeutic agents. Exemplary such methods include combining (a) at least one therapeutic agent, (b) at least one ionization-stabilizing excipient, (c) at least one sustained-release modifier, and (d) an aprotic solvent, resulting in a storage-stable SR formulation of a therapeutic peptide or small molecule in a ready-to-use solution.

[0029] Without wishing to be bound by theory, sustained release modifiers, particularly divalent cations (e.g., Zn ++It is believed that zinc-containing compounds capable of donating ions can form coordination complexes with one or more aspartic acid and / or histidine residues on peptide therapeutics, thereby preventing the formation of amyloid-like fibrils (a hallmark of solution instability of therapeutic peptides). It is theorized that the relatively low solubility of zinc-peptide complexes in water results in sustained release of the peptide from the complex when administered to an animal (e.g., a vertebrate or a human), thereby resulting in release of the peptide from the injection site into the bloodstream with prolonged release kinetics compared to uncomplexed (immediate-release) peptide formulations (see, e.g., Trading, F. et al., Eur. J. Pharmacol. 7:206-210 (1969)). Thus, the formulation approaches described herein are believed to be particularly useful in preparing storage-stable SR formulations of various aspartic acid and / or histidine-containing therapeutic peptides, including, but not limited to, glucagon (and its analogs, GLP-1, GLP-2, adrenocorticotropic hormone (ACTH), leuprolide, hirudin, insulin, pramlintide, exendin, exenatide, gastric inhibitory peptide, calcitonin, calcitonin gene-related peptide, amylin, adrenomedullin, angiotensin, and the like. One of skill in the art can readily determine other peptides containing one or more aspartic acid and / or histidine residues that may be suitably used in preparing the formulations of the present invention.

[0030] Therapeutic molecules typically require an optimal or beneficial ionization profile to exhibit prolonged stability when dissolved in an aprotic polar solvent system. Maintaining a beneficial ionization profile of a therapeutic molecule dissolved in an aprotic polar solvent system can be achieved by using at least one ionization-stabilizing excipient. In certain aspects, the therapeutic molecule does not need to be dried from a buffered aqueous solution before reconstitution in an aprotic polar solvent system. The ability to use existing (e.g., commercially available) devices and avoid the need to dry a therapeutic molecule (e.g., a peptide) from a buffered aqueous solution can save significant time and money throughout various product development stages.

[0031] A stable solution of a therapeutic agent solubilized in a non-aqueous aprotic polar solvent (e.g., DMSO) can be prepared by adding a specific amount of a compound or combination of compounds that function as an ionization-stabilizing excipient. Without wishing to be bound by theory, it is believed that the ionization-stabilizing excipient may act as a proton source (e.g., a molecule that can donate a proton to a therapeutic molecule) in the aprotic polar solvent system that can protonate an ionogenic group on the therapeutic molecule, such that the therapeutic molecule has an ionization profile that exhibits improved physical and chemical stability in the aprotic polar solvent system. Alternatively, the ionization-stabilizing excipient may act as a proton sink (e.g., a molecule or moiety that can accept / remove a proton from a therapeutic molecule), such that the therapeutic molecule has an ionization profile that exhibits improved physical and chemical stability in the aprotic polar solvent system.

[0032] Certain embodiments relate to formulations comprising an ionization stabilizing excipient at a concentration of at least 0.01, 0.1, 0.5, 1, 10, or 50 mM to 10, 50, 75, 100, 500, 1000 mM, at most 0.01, 0.1, 0.5, 1, 10, or 50 mM to 10, 50, 75, 100, 500, 1000 mM, or about 0.01, 0.1, 0.5, 1, 10, or 50 mM to 10, 50, 75, 100, 500, 1000 mM, or up to the solubility limit of the ionization stabilizing excipient in the aprotic polar solvent system. In certain aspects, the concentration of the ionization stabilizing excipient is about 0.1 mM to about 100 mM, particularly about 1 mM to about 10 mM, such as about 1 mM, about 2 mM, about 3 mM, about 4 mM, about 5 mM, about 6 mM, about 7 mM, about 8 mM, about 9 mM, and about 10 mM. In certain embodiments, the ionization stabilizing excipient can be a suitable inorganic acid, such as hydrochloric acid, sulfuric acid, nitric acid, etc. In certain aspects, the ionization stabilizing excipient can be an organic acid, such as an amino acid, an amino acid derivative, or a salt of an amino acid or amino acid derivative (examples include glycine, trimethylglycine (betaine), glycine hydrochloride, and trimethylglycine (betaine) hydrochloride). In a further aspect, the amino acid can be glycine or the amino acid derivative trimethylglycine. In certain aspects, the peptide contains fewer than 150, 100, 75, 50, or 25 amino acids. In a further aspect, the aprotic solvent system comprises DMSO. Aprotic solvent can be deoxygenated, for example, deoxygenated DMSO.In certain embodiments, the formulation can be prepared by first adding ionization stabilizing excipient to aprotic polar solvent system, and then adding therapeutic molecule.Alternatively, therapeutic molecule can be first solubilized in aprotic polar solvent system, and then adding ionization stabilizing excipient.In a further aspect, ionization stabilizing excipient and therapeutic molecule can be simultaneously solubilized in aprotic polar solvent system.In certain aspects, therapeutic agent is glucagon, glucagon analog, or their salt.

[0033] Another aspect of the present invention relates to a method for stably formulating a therapeutic agent (e.g., a peptide or small molecule), comprising the steps of: (a) calculating or determining appropriate ionization stabilizing excipients (e.g., proton concentrations) needed to achieve a stabilized ionization profile of the targeted therapeutic agent (e.g., a peptide or small molecule) in an aprotic polar solvent system; (b) mixing at least one ionization stabilizing excipient with the aprotic polar solvent system to obtain a suitable ionization environment that provides the ionization profile determined in (a); and (c) solubilizing a sustained-release modifier and the targeted therapeutic agent in an aprotic solvent having a suitable environment to physically and chemically stabilize the therapeutic agent. In certain non-limiting aspects, the therapeutic agent is chemically or physically stable at room temperature, refrigerated temperature (e.g., about 2°C to about 10°C, or about 2°C, about 3°C, about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, about 9°C, or about 10°C), or at temperatures below zero (e.g., about −4°C to about −80°C, or about −4°C, about −10°C, about −15°C, about −20°C, about −25°C, about −40°C, about −45°C, about −50°C, about −60°C, about −70°C, or about −80°C) for at least or about 0.25, 0.5, 1, 2, 3, 4, or 5 years, more preferably about 0.25 to about 2 years. In certain aspects, dissolution of the therapeutic agent in the aprotic polar solvent system and addition of the ionizable stabilizing excipient and sustained-release modifier can be performed in any order or simultaneously; thus, the ionizable stabilizing excipient and sustained-release modifier can be mixed first, followed by dissolution of the therapeutic agent; or the therapeutic agent can be dissolved first, followed shortly thereafter (e.g., within about 5 minutes) by addition of the ionizable stabilizing excipient and sustained-release modifier; or the ionizable stabilizing excipient, sustained-release modifier, and / or therapeutic agent can be added or dissolved simultaneously in the aprotic polar solvent system. In some embodiments, the addition of the ionizable stabilizing excipient can be performed before the addition of the therapeutic agent and / or sustained-release modifier to facilitate dissolution in the aprotic polar solvent system. One or more additional formulation components (e.g., preservatives, surfactants, polysaccharides, sugar alcohols, etc.) can be added to the formulation either before or after the addition of the therapeutic agent.In further aspects, the entire amount of components (e.g., therapeutic agent or ionization-stabilizing excipient) need not be mixed at a particular time; i.e., a portion of one or more components can be mixed first, second, or simultaneously, and another portion can be mixed first, second, or simultaneously at another time. The concentration of the therapeutic agent and / or ionization-stabilizing excipient added to the solution can be between 0.01, 0.1, 1, 10, 100, 1000 mM, or up to its solubility limit, including all values ​​and ranges therebetween. In certain aspects, the aprotic polar solvent system is deoxygenated. In further aspects, the aprotic polar solvent in the solvent system comprises, consists essentially of, or consists of DMSO or deoxygenated DMSO.

[0034] In a further aspect of the present invention, a method for treating or preventing a condition, disease, disorder, etc. is disclosed, comprising administering to a subject in need thereof an effective amount of a formulation of the present invention to treat or prevent the condition, disease, disorder, etc. Any appropriate dose of a therapeutic agent (e.g., a protein, peptide, or small molecule) can be administered in the methods of the present invention. The administered dose can, of course, vary depending on known factors, such as the pharmacodynamic characteristics of the individual compounds, salts, or combinations, the age, health, or weight of the subject, the nature and extent of symptoms, the metabolic characteristics of the drug and the patient, the type of concurrent treatment, the frequency of treatment, or the desired effect. In certain aspects, hypoglycemia can be treated by administering a formulation described herein containing an effective amount of glucagon.

[0035] The stable SR formulations described herein are useful for parenteral injection of any therapeutic agent (protein, peptide, and / or small molecule) that has limited or poor stability or solubility in an aqueous environment. In certain aspects, the formulations described herein are provided as injectable formulations. The injectable formulations can be administered to the epidermis, skin, subcutaneous or intramuscular layer of a patient. In certain aspects, the formulations are administered intradermally.

[0036] Therefore, in some embodiments, the therapeutic agent or peptide or its salt is selected from the group consisting of glucagon, pramlintide, insulin, icatibant, leuprolide, LHRH agonist, parathyroid hormone (PTH), adrenocorticotropic hormone (ACTH), hirudin, amylin, botulinum toxin, hematide, amyloid peptide, cholecystokinin, conotoxin, gastric inhibitory peptide, antibody (can be monoclonal or polyclonal) or fragment thereof, immunogenic peptide (e.g., peptide or peptide complex derived from virus, bacteria, or any prokaryotic or eukaryotic organism or cell thereof), insulin-like growth factor, growth hormone-releasing factor, antibacterial factor, glatiramer, glucagon-like peptide-1 (GLP-1), GLP-1 agonist, exenatide, its analog, and mixtures thereof. In one embodiment, the peptide is glucagon or a glucagon analog or glucagon peptidomimetic. In another embodiment, the peptide is parathyroid hormone. In another embodiment, the peptide is ACTH. In yet another embodiment, the peptide is leuprolide. In yet another embodiment, the peptide is glatiramer. In yet another embodiment, the peptide is icatibant. In yet another embodiment, the first peptide is pramlintide and the second peptide is insulin. In yet another embodiment, the first peptide is glucagon and the second peptide is exenatide. In other embodiments, the stable formulations used in accordance with the present invention comprise co-formulations or mixtures of compounds of the type described herein, e.g., at least one peptide, at least one small molecule, and combinations thereof.

[0037] definition Terms such as "container," "reservoir," "infusion set," "pump," "formulation flow path," "fluid flow path," and the like should be interpreted as interchangeable and equivalent, referring to components that directly contact the administered or stored formulation, which may interact with the component and its surface. These terms connote any and all components that the formulation may come into contact with during storage (e.g., pump reservoir) and delivery (e.g., pump and the fluid flow path within an infusion set when connected in series to the pump). The term "infusion set," as used herein, may be interpreted to include both self-contained infusion sets (i.e., those contained within patch pumps) and the complete tubing system, typically external to the pump, that connects the pump to the pump user. In certain configurations, external infusion sets include a cannula (e.g., for subcutaneous administration), an adhesive mount, a quick disconnect, and a pump cartridge connector (e.g., a Luer connector).

[0038] The terms "formulation" and "composition" may be used interchangeably herein and, as used herein, refer to a mixture of at least two components to produce a preparation that includes all of those components, some of those components, or a complex or reaction mixture or reactant resulting from the mixing of those components.

[0039] The term "dissolution," as used herein, refers to the process by which a substance in a gaseous, solid, or liquid state becomes a solute, a dissolved component of a solvent, forming a solution of the gas, liquid, or solid in the solvent. In certain aspects, a therapeutic agent or excipient, such as an ionizable stabilizing excipient or sustained-release modifier, or other component, is present in an amount up to its solubility limit or is completely solubilized. The term "dissolution" refers to the incorporation of a gas, liquid, or solid into a solvent to form a solution.

[0040] The term "elastomer," as used herein, refers to a natural or synthetic polymer that has elastic properties. The terms "elastomer" and "rubber" may be used interchangeably herein.

[0041] The term "excipient," as used herein, refers to a natural or synthetic substance (a component other than the active ingredient) formulated with an active or therapeutic ingredient of a pharmaceutical for purposes of stabilization, bulking, or to provide a therapeutic enhancement to the active ingredient in the final dosage form, e.g., to facilitate drug absorption, reduce viscosity, increase or decrease aqueous or non-aqueous solubility, adjust osmolality, reduce injection site discomfort, lower the freezing point, or enhance stability. Excipients can also be useful in aiding in in vitro stability, e.g., preventing denaturation or aggregation during the expected storage period, as well as aiding in handling of the active agent of interest during the manufacturing process, e.g., by promoting powder flow or non-stick properties.

[0042] In the context of the present invention, a "small molecule drug" is a biologically active compound (and its salts) that can produce a desired, beneficial, and / or pharmacological effect in a subject. These "small molecule drugs" are organic or inorganic compounds. Therefore, in the context of the present invention, small molecule drugs are not polymeric compounds. Typically, small molecule drugs have a molecular weight of less than approximately 1000 daltons. Certain small molecule drugs are "moisture sensitive" in that they become increasingly unstable in the presence of water. In addition, salts that can be used with small molecule drugs are known to those skilled in the art and include salts with inorganic acids, organic acids, inorganic bases, or organic bases.

[0043] The term "therapeutic agent" or "therapeutic" encompasses proteins, peptides, small molecule drugs, and pharmaceutically acceptable salts thereof. Useful salts are known to those skilled in the art and include salts with inorganic acids, organic acids, inorganic bases, or organic bases. Therapeutic agents useful in the present invention are proteins, peptides, and small molecule compounds that, either alone or in combination with other pharmaceutical excipients or inactive ingredients, provide a desired, beneficial, and often pharmacological effect when administered to humans or animals.

[0044] The terms "peptide" and "peptide compound" refer to amino acid or amino acid-like (peptidomimetic) multimers of up to about 200 amino acid residues linked together by amide (CONH) or other linkages. In certain aspects, peptides can be up to 150, 100, 80, 60, 40, 20, or 10 amino acids. "Protein" and "proteinaceous compound" refer to multimers of more than 200 amino acid residues linked together by amide bonds. Analogs, derivatives, agonists, antagonists, and pharmaceutically acceptable salts of any of the peptide or proteinaceous compounds disclosed herein are included within these terms. These terms also include peptides, proteins, peptide compounds, and proteinaceous compounds having D-amino acids, modified, derivatized, or naturally occurring amino acids in the D or L configuration, and / or peptidomimetic units as part of their structure.

[0045] "Analog" and "analog," when referring to a peptide or protein, refer to a modified peptide or protein in which one or more amino acid residues of the peptide or protein have been substituted with other amino acid residues, or one or more amino acid residues have been deleted from the peptide or protein, or one or more amino acid residues have been added to the peptide or protein, or any combination of such modifications. Such addition, deletion, or substitution of amino acid residues can occur at any point, or points, along the primary structure that makes up the peptide, including the N-terminus of the peptide or protein and / or the C-terminus of the peptide or protein.

[0046] A "derivative," in reference to a parent peptide or protein, refers to a chemically modified parent peptide or protein or analog thereof, in which at least one substitution is not present in the parent peptide or protein or analog thereof. One such non-limiting example is a covalently modified parent peptide or protein. Typical modifications are amides, carbohydrates, alkyl groups, acyl groups, esters, pegylation, etc.

[0047] A "single-phase solution" refers to a solution prepared from a therapeutic agent dissolved in a solvent or solvent system (e.g., a mixture of two or more solvents (e.g., a solvent and a co-solvent)) in which the therapeutic agent is completely dissolved in the solvent or solvent system and no particulate matter is visible, such that the solution can be described as optically clear. A single-phase solution may also be referred to as a "single-phase system," which is distinguished from a "two-phase system," in that the latter is formed from particulate matter (e.g., a powder) suspended in a fluid.

[0048] "Inhibition," "reduction," or any variation of these terms includes any measurable decrease or complete inhibition that achieves the desired result.

[0049] "Effective" or "treatment" or "prevention," or any variation of these terms, means sufficient to achieve a desired, expected, or intended result.

[0050] "Chemical stability," when referring to a therapeutic agent, refers to the formation of an acceptable proportion of degradation products via chemical pathways, such as oxidation and / or hydrolysis and / or fragmentation and / or other chemical degradation pathways. In particular, formulations of the type described herein can be considered chemically stable if no more than about 20% degradation products are formed after at least one year of storage at the product's intended storage temperature (e.g., refrigerated storage or storage below zero degrees Celsius), or after one, two, or preferably three months of storage under accelerated conditions (25°C / 60% relative humidity). In some embodiments, a chemically stable formulation has less than 30%, 25%, 20%, 15%, 10%, 5%, 4%, 3%, 2%, or 1% degradation products formed after extended storage at the product's intended storage temperature.

[0051] "Physical stability," when referring to a therapeutic agent, refers to the formation of an acceptable proportion of aggregates (e.g., dimers, trimers, and higher forms). In particular, a formulation is considered physically stable if about 15% or less aggregates form after at least one year of storage at the product's intended storage temperature (e.g., refrigerated or subzero storage), or after one, two, and preferably at least three months of storage at 25°C / 60% relative humidity. In some embodiments, a physically stable formulation has less than 15%, less than 10%, less than 5%, less than 4%, less than 3%, less than 2%, or less than 1% aggregates formed after extended storage at the product's intended storage temperature.

[0052] A "stable formulation" refers to a formulation in which at least about 65% of the therapeutic agent (e.g., a peptide or salt thereof) remains chemically and physically stable after storage at room temperature for at least one month or storage at refrigerated or sub-zero temperatures for up to at least one year. Particularly preferred formulations are those in which at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the therapeutic agent remains chemically and physically stable under these storage conditions. Particularly preferred stable formulations are those that do not exhibit degradation after sterilizing irradiation (e.g., gamma, beta, or electron beam).

[0053] As used herein, "parenteral injection" refers to the administration of a therapeutic agent (e.g., a peptide or small molecule) through a route other than the alimentary canal—any administration not via the digestive tract—e.g., intravenous infusion, intranasal administration, buccal administration, transdermal administration, or injection under or through one or more layers of the skin or mucosa of an animal, e.g., a human. Standard parenteral injections are performed into subcutaneous, intramuscular, or intradermal tissues of an animal, e.g., a human. These deeper sites are targeted because the tissues expand more readily than shallower skin sites to accommodate the injection volumes required to deliver most therapeutic agents, e.g., 0.1 to 3.0 cc (mL).

[0054] The term "intradermal" includes administration into the epidermal, dermal, or subcutaneous skin layers.

[0055] As used herein, the term "aprotic polar solvent" refers to a polar solvent that does not contain acidic hydrogen and therefore does not act as a hydrogen bond donor. Polar aprotic solvents include, but are not limited to, dimethyl sulfoxide (DMSO), dimethylformamide (DMF), ethyl acetate, n-methylpyrrolidone (NMP), dimethylacetamide (DMA), and propylene carbonate.

[0056] As used herein, the term "aprotic polar solvent system" refers to a solution in which the solvent is a single aprotic polar solvent (e.g., neat DMSO) or a mixture of two or more aprotic polar solvents (e.g., a mixture of DMSO and NMP), or a mixture of at least one aprotic polar solvent and another pharmaceutically acceptable solvent system. In a further aspect, the term "aprotic polar solvent system" refers to a solution in which the solvent is one or more aprotic polar solvents mixed with an amount of water, for example, water, in a v / v ratio of at least about 99.9% aprotic solvent to about 0.1% water to a maximum of at least about 50% aprotic solvent to about 50% water.

[0057] As used herein, "residual moisture" may refer to the moisture (typically, residual water) remaining in a drug powder after preparation by the manufacturer / supplier. Typical powders often have a residual moisture content ranging up to 10% (w / w). When these powders are dissolved in an aprotic polar solvent system, the residual moisture in the powder is incorporated into the formulation. Furthermore, aprotic polar solvents may also contain a certain level of residual moisture. For example, a newly opened bottle of USP-grade DMSO may contain up to 0.1% (w / w) moisture. Residual moisture differs from "added moisture," in which water is intentionally added to a formulation, for example, to act as a cosolvent or to depress the freezing point of an aprotic polar solvent system. Moisture can also be introduced into a formulation upon the addition of ionizable stabilizing excipients (e.g., through the addition of an inorganic acid (e.g., 1N HCl or H2SO4) from an aqueous stock solution) or through the addition of water (e.g., water for injection). The total water content (% v / v unless otherwise stated) in the freshly prepared formulation is due to contributions from both residual and added water.

[0058] As used herein, a "device flow path" refers to a portion of a device that may come into contact with a formulation / solution / solvent during administration of the formulation / solution / solvent to a subject using the device. In some aspects, the device may be an infusion set in series with a pump that can parenterally administer the formulation / solution / solvent to a subject through various needles and / or tubing. In other aspects, the device may be a patch pump that is attached directly to the patient and does not require the use of an external infusion set connected in series with the pump.

[0059] The terms "about" or "approximately" or "substantially unchanged" are defined as closely as understood by one of ordinary skill in the art, and in one non-limiting embodiment, the term is defined as within 10%, preferably within 5%, more preferably within 1%, and most preferably within 0.5%. Additionally, "substantially non-aqueous" refers to less than 5%, 4%, 3%, 2%, 1% or less water by weight or volume.

[0060] A "pharmaceutically acceptable" ingredient, excipient, or component is one that is suitable for use in humans and / or animals without producing excessive adverse side effects (e.g., toxicity, irritation, and allergic response) commensurate with a reasonable benefit / risk ratio.

[0061] "Pharmaceutically acceptable carrier" means a pharmaceutically acceptable solvent, suspending agent, or vehicle for delivering a drug compound of the present invention to a mammal, eg, a human.

[0062] As used herein, an "ionization-stabilizing excipient" is an excipient that establishes and / or maintains a particular ionization state for a therapeutic agent. In certain aspects, an ionization-stabilizing excipient may be or includes a molecule that, under appropriate conditions, donates at least one cation, particularly at least one divalent cation, or is a cation (particularly a divalent cation)-donating compound or source.

[0063] As used herein, a "mineral acid" is an acid derived from one or more inorganic compounds. Thus, an inorganic acid may also be referred to as an "inorganic acid." Inorganic acids can be monoprotic or polyprotic (e.g., diprotic, triprotic, etc.). Non-limiting examples of inorganic acids include hydrochloric acid (HCl), nitric acid (HNO), sulfuric acid (HSO), and phosphoric acid (HPO).

[0064] As used herein, an "inorganic base" (which may equivalently and alternatively be referred to as an "inorganic base") is a base derived from one or more inorganic compounds. Many, but not all, inorganic bases are typically classified as "strong bases," and non-limiting examples of inorganic bases include sodium hydroxide (NaOH), potassium hydroxide (KOH), magnesium hydroxide (Mg(OH)), and calcium hydroxide (Ca(OH)).

[0065] As used herein, an "organic acid" is an organic compound that has acidic properties (i.e., can function as a proton source). A carboxylic acid, such as acetic acid or citric acid, is an example of an organic acid. Other known examples of organic acids include, but are not limited to, alcohols, thiols, enols, phenols, and sulfonic acids. Organic acids can be monoprotic or multiprotic (e.g., diprotic, triprotic, etc.).

[0066] As used herein, an "organic base" is an organic compound that has basic properties (i.e., can function as a proton acceptor / sink). Many, but not all, organic bases contain a nitrogen atom (e.g., amines), and non-limiting examples of organic bases include amino acids (e.g., histidine, arginine, lysine), pyridine, imidazole, and tromethamine. An organic base can accept one or more protons per molecule.

[0067] "Charge profile," "charge state," "ionization," "ionization state," and "ionization profile" may be used interchangeably to refer to the ionization state based on the protonation and / or deprotonation of the ionogenic groups of the peptide.

[0068] As used herein, a "co-formulation" is a formulation containing two or more therapeutic agents dissolved in an aprotic polar solvent system. The therapeutic agents may belong to the same class (e.g., a co-formulation containing two or more therapeutic peptides, such as insulin and pramlintide, or glucagon and GLP-1), or the therapeutic agents may belong to different classes (e.g., a co-formulation containing one or more therapeutic small molecules and one or more therapeutic peptide molecules, such as GLP-1 and lisofylline).

[0069] When used in conjunction with the word "comprising" in the claims and / or specification, the use of the words "a" or "an" can mean "one," but can also mean "one or more," "at least one," and "one or more than one."

[0070] "Comprising" (and any form of comprising, e.g., "comprise" and "comprises"), "having" (and any form of having, e.g., "have" and "has"), "including" (and any form of including, e.g., "includes" and "include") or "containing" (and any form of containing, e.g., "contains" and "contain") is inclusive and open-ended and does not exclude additional, unmentioned elements or method steps.

[0071] [The present invention 1001] (a) at least one therapeutic agent; (b) at least one ionizable stabilizing excipient; and (c) at least one sustained release modifier; and (d) aprotic polar solvents and 1. A sustained release therapeutic formulation comprising: The formulation is storage stable for at least six months at 25°C, and the formulation, when administered to a patient, results in therapeutic levels of the therapeutic agent in the patient's blood for an extended period of time compared to an immediate release formulation containing the same therapeutic agent. Sustained release therapeutic formulations. [The present invention 1002] 1001. The formulation of the present invention, wherein the therapeutic agent is a peptide. [The present invention 1003] The formulation of claim 1002, wherein the peptide is a glucagon peptide, a glucagon analog, a glucagon mimetic, or a salt thereof. [The present invention 1004] 1001. The formulation of claim 1001, wherein the ionizable stabilizing excipient is an inorganic acid. [The present invention 1005] 1004. The formulation of claim 10, wherein the inorganic acid is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid. [The present invention 1006] 1001. The formulation of claim 1001, wherein the sustained-release modifier is a divalent cation-donating compound. [The present invention 1007] 1006. The formulation of claim 10, wherein the divalent cation-donating compound is a zinc-containing compound. [The present invention 1008] 1007. The formulation of claim 10, wherein the zinc-containing compound is a zinc salt. [The present invention 1009] 1008. The formulation of claim 10, wherein the zinc salt is selected from the group consisting of zinc acetate, zinc chloride, and zinc sulfate. [The present invention 1010] 1008. The formulation of claim 10, wherein the zinc salt is zinc sulfate. [The present invention 1011] 1001. A formulation of the present invention, wherein the aprotic polar solvent is DMSO. [The present invention 1012] 1001. The formulation of claim 1001, wherein the therapeutic agent is glucagon, the ionizable stabilizing excipient is an inorganic acid, the sustained-release modifier is a zinc salt, and the aprotic solvent is DMSO. [The present invention 1013] A method of treating or preventing hypoglycemia by administering to a subject in need thereof an effective amount of a formulation of the present invention. [The present invention 1014] The method of claim 1013, wherein the formulation is introduced into the subject via parenteral administration. [The present invention 1015] The method of claim 1014, wherein parenteral administration is via injection or infusion. [The present invention 1016] The method of claim 1015, wherein the injection is subcutaneous, intradermal, or intramuscular. [The present invention 1017] The method of claim 1015, wherein the infusion is intravenous. [The present invention 1018] The method of claim 1015, wherein the infusion is achieved by pump infusion. [The present invention 1019] The method of claim 1018, wherein the pump infusion comprises continuous or bolus pump infusion, or a combination thereof. [The present invention 1020] A method of making a storage-stable sustained-release therapeutic formulation, comprising the steps of combining at least one ionization-stabilizing excipient, at least one sustained-release modifier, an aprotic polar solvent, and at least one therapeutic agent, thereby forming a storage-stable therapeutic formulation that, when administered to a patient, results in the presence of therapeutic levels of the therapeutic agent in the patient's blood for an extended period of time compared to an immediate-release formulation containing the same therapeutic agent. [The present invention 1021] The method of claim 1020, wherein the therapeutic agent is a peptide. [The present invention 1022] The method of claim 1021, wherein the peptide is a glucagon peptide, a glucagon analog, a glucagon mimetic, or a salt thereof. [The present invention 1023] The method of claim 1020, wherein the ionizable stabilizing excipient is an inorganic acid. [The present invention 1024] The process of claim 1023, wherein the inorganic acid is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid. [The present invention 1025] The method of claim 1020, wherein the sustained-release modifier is a divalent cation-donating compound. [The present invention 1026] The method of claim 1025, wherein the divalent cation-donating compound is a zinc-containing compound. [The present invention 1027] The method of claim 1026, wherein the zinc-containing compound is a zinc salt. [The present invention 1028] 1027. The method of claim 1027, wherein the zinc salt is selected from the group consisting of zinc acetate, zinc chloride, and zinc sulfate. [The present invention 1029] 1027. The method of claim 1027, wherein the zinc salt is zinc sulfate. [The present invention 1030] The method of claim 1020, wherein the aprotic polar solvent is DMSO. [The present invention 1031] The method of claim 1020, wherein the therapeutic agent is glucagon, the ionizable stabilizing excipient is an inorganic acid, the sustained-release modifier is a zinc salt, and the aprotic solvent is DMSO. [The present invention 1032] A method of diagnosing a disease or physical disorder in a human patient by introducing to a patient suffering from or susceptible to the disease or disorder an effective amount of a formulation of the present invention 1001 as an adjunct to a diagnostic test, and performing the diagnostic test on the patient. [The present invention 1033] The method of claim 1032, wherein the therapeutic agent is a peptide. [The present invention 1034] The method of claim 1033, wherein the peptide is a glucagon peptide, a glucagon analog, a glucagon mimetic, or a salt thereof. [This invention 1035] The method of claim 1032, wherein the ionizable stabilizing excipient is an inorganic acid. [The present invention 1036] The method of claim 1032, wherein the sustained-release modifier is a divalent cation-donating compound. [This invention 1037] The method of claim 1036, wherein the divalent cation-donating compound is a zinc-containing compound. [The present invention 1038] The method of claim 1032, wherein the zinc-containing compound is a zinc salt. [This invention 1039] The method of claim 1038, wherein the zinc salt is selected from the group consisting of zinc acetate, zinc chloride, and zinc sulfate. [The present invention 1040] The method of claim 1038, wherein the zinc salt is zinc sulfate. [This invention 1041] The method of claim 1032, wherein the aprotic polar solvent is DMSO. [The present invention 1042] The method of claim 1032, wherein the therapeutic agent is glucagon, the ionizable stabilizing excipient is an inorganic acid, the sustained-release modifier is a zinc salt, and the aprotic solvent is DMSO. [This invention 1043] The method of claim 1032, wherein the patient has or is susceptible to Alzheimer's disease. [This invention 1044] The method of claim 1032, wherein the patient is suffering from or susceptible to growth hormone deficiency. [This invention 1045] The method of claim 1032, wherein the patient is suffering from or susceptible to a gastrointestinal disorder. [The present invention 1046] The method of claim 1032, wherein the diagnostic test is a radiological examination of the patient's gastrointestinal tract. [This invention 1047] The method of claim 1032, wherein the formulation is introduced into the patient intravenously, intramuscularly, or intradermally. [This invention 1048] The formulation of claim 1001, further comprising at least one polymer suitable for use in preparing a sustained release formulation of the peptide. [This invention 1049] The formulation of claim 1048, wherein the polymer is PLGA. [The present invention 1050] The formulation of claim 1049, wherein the PLGA is an ester-terminated PLGA or an acid-terminated PLGA. [This invention 1051] A formulation of 1048 according to the invention, which provides for complete release of said peptide from said formulation into the bloodstream of an animal administered said formulation within a period of 7 to 14 days. Other objects, features, and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and examples, while indicating specific embodiments of the present invention, are given by way of illustration only. In addition, it is contemplated that changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art from this detailed description. [Brief explanation of the drawings]

[0072] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

[0073] [Figure 1] 1A-1B are photographs showing a visual assessment of the physical appearance of exemplary formulations of the present invention immediately after formulation (i.e., at T=0): Figure 1A: Formulation A-1; Figure 1B: Formulation A-2 (see Table 1 in Example 1 hereinbelow for formulation components). [Figure 2] Figures 2A-2B are a series of photographs showing the stability of SR glucagon formulations of the present invention. Samples were photographed after 6 months of storage at -20°C and visually examined for evidence of glucagon degradation (e.g., discoloration, precipitation, gelation, aggregation). Images were taken against a white background (Figure 2A) to indicate any visible discoloration or against a black background (Figure 2B) to indicate any visible aggregation / fibrillation relative to a control (non-SR) glucagon formulation. In both Figures 2A and 2B, samples are arranged from left to right as follows: non-SR (control); Formulation A-1; Formulation A-2; Formulation B-1; Formulation B-2; Formulation C-1; Formulation C-2. See Table 1 in Example 1 hereinbelow for formulation components. [Figure 3] Figures 3A-3B are a series of photographs showing the stability of SR glucagon formulations of the present invention. Samples were photographed after 6 months of storage at 5°C and visually examined for evidence of glucagon degradation (e.g., discoloration, precipitation, gelation, aggregation). Images were taken against a white background (Figure 3A) to indicate any visible discoloration or against a black background (Figure 3B) to indicate any visible aggregation / fibrillation relative to a control (non-SR) glucagon formulation. In both Figures 3A and 3B, samples are arranged from left to right as follows: non-SR (control); Formulation A-1; Formulation A-2; Formulation B-1; Formulation B-2; Formulation C-1; Formulation C-2. See Table 1 in Example 1 hereinbelow for formulation components. [Figure 4]Figures 4A-4B are a series of photographs showing the stability of SR glucagon formulations of the present invention. Samples were photographed after 6 months of storage at 25°C and visually examined for evidence of glucagon degradation (e.g., discoloration, precipitation, gelation, aggregation). Images were taken against a white background (Figure 4A) to indicate any visible discoloration or against a black background (Figure 4B) to indicate any visible aggregation / fibrillation relative to a control (non-SR) glucagon formulation. In both Figures 4A and 4B, samples are arranged from left to right as follows: non-SR (control); Formulation A-1; Formulation A-2; Formulation B-1; Formulation B-2; Formulation C-1; Formulation C-2. See Table 1 in Example 1 hereinbelow for formulation components. [Figure 5] Figures 5A-5B are a series of photographs showing the stability of SR glucagon formulations of the present invention. Samples were photographed after 6 months of storage at 40°C / 75% relative humidity and visually examined for evidence of glucagon degradation (e.g., discoloration, precipitation, gelation, aggregation). Images were taken against a white background (Figure 5A) to indicate any visible discoloration or against a black background (Figure 5B) to indicate any visible aggregation / fibrillation relative to a control (non-SR) glucagon formulation. In both Figures 5A and 5B, samples are arranged from left to right as follows: non-SR (control); Formulation A-1; Formulation A-2; Formulation B-1; Formulation B-2; Formulation C-1; Formulation C-2. See Table 1 in Example 1 hereinbelow for formulation components. [Figure 6] 1 is a line graph showing a comparative pharmacokinetic (PK) study of an exemplary SR glucagon formulation of the present invention compared to an immediate-release control glucagon formulation. The graph shows the mean ± SD (n=3) plasma glucagon levels and half-life of selected formulations in a rat PK study. ●: Control (commercially available immediate-release glucagon formulation); ▲: SR glucagon formulation (Formulation A-1; see Table 1 in Example 1). [Figure 7]Figures 7A-7D are a collection of photographs and line graphs showing the stability of SR glucagon formulations of the present invention. Samples were evaluated for purity via RP-UHPLC and photographed after 12 months of storage at either 5°C (Figures 7A, 7B) or 25°C (Figures 7C, 7D). See Table 1 in Example 1 hereinbelow for formulation components. [Figure 8] Figures 8A-8B are a pair of line graphs showing comparative pharmacokinetic (PK) studies of certain SR glucagon formulations of the present invention compared to an immediate-release control glucagon formulation. The graphs show the mean ± SD (n=3) plasma glucagon levels and half-lives of selected formulations in a rat PK study. Figure 8A: Formulation Groups 1-5; Figure 8B: Formulation Groups 1 and 6-8. See Table 3 in Example 2 hereinbelow for formulation components. [Figure 9] Figures 9A-9D are a collection of line graphs showing the stability of long-acting ("LA") glucagon formulations of the present invention. The formulations were prepared as described in Example 3 hereinbelow and evaluated for purity via RP-UHPLC after 3 months of storage at -20°C (Figure 9A), 5°C (Figure 9B), 25°C (Figure 9C), or 40°C (Figure 9D). IR: immediate-release GVOKE® glucagon (100 mg / mL glucagon, 126 mM H2SO4); A: 100 mg / mL glucagon, 126 mM H2SO4, 40% ester-terminated PLGA; B: 100 mg / mL glucagon, 126 mM H2SO4, 5% (w / v) trehalose, 40% ester-terminated PLGA; C: 100 mg / mL glucagon, 126 mM H2SO4, 40% acid-terminated PLGA. [Figure 10]1 is a line graph showing a comparative pharmacokinetic (PK) study of certain LA glucagon formulations of the present invention compared to an immediate-release control glucagon formulation. The graph shows the mean ± SD (n=3) plasma glucagon levels and half-life of selected formulations in a rat PK study. Group 1: immediate-release GVOKE® glucagon formulation; Group 2: Resomer® RG502 PLGA glucagon formulation; Group 3: Resomer RG502 PLGA and sucrose acetate isobutyrate (SAIB) glucagon formulation; Group 4: paste-like high-concentration Xeriject™ glucagon formulation (Xeris Pharmaceuticals, Chicago, IL) (see U.S. Pat. Nos. 8,110,209, 8,790,679, and 9,314,424, which are incorporated by reference in their entireties); Group 5: glucagon formulations containing triacetin; Group 6: glucagon formulations containing benzyl benzoate. [Figure 11] Figures 11A-11B are a pair of line graphs showing the contrasting release kinetics in an in vitro assay system of certain LA glucagon formulations of the invention. The graphs show the mean ± SD (n=3) amount of glucagon in aqueous release media over time. Figure 11A: Formulation containing 250 mg / mL glucagon, 40% Resomer® RG502 PLGA in acidified DMSO; Figure 11B: Formulation containing 100 mg / mL glucagon, 40% Resomer® RG502 PLGA in acidified DMSO (bottom line) or 100 mg / mL glucagon, 40% Resomer® RG502H PLGA in acidified DMSO (top line). [Figure 12] 1 is a line graph showing the comparative release kinetics in an in vitro assay system of certain LA glucagon formulations of the present invention. The graph shows the mean ± SD (n=3) amount of glucagon in aqueous release medium over time. The formulation components, specifically the glucagon:PLGA ratio, are indicated to the right of the graph. DETAILED DESCRIPTION OF THE INVENTION

[0074] Detailed Description of the Invention When prepared as an aqueous solution, standard small molecules, peptides, and protein molecules can be subject to multiple physical and chemical degradation pathways. For many of these therapeutic molecules, degradation pathways catalyzed, mediated, and / or accelerated by water (e.g., hydrolysis, racemization, deamidation) cannot be avoided, and as a result, the molecules cannot be sufficiently stabilized. Therefore, many therapeutic agents cannot be prepared as stable solutions for parenteral injection, but instead are prepared as powders that are reconstituted immediately before use.

[0075] To address the physical and / or chemical instability that many therapeutic molecules exhibit in water, formulations can be prepared in which the therapeutic agent is dissolved in a biocompatible non-aqueous liquid, such as an aprotic polar solvent (e.g., DMSO). Previous non-aqueous formulations are based, at least in part, on the premise that limiting the water content of the formulation promotes physical and chemical stability by inhibiting water-mediated degradation pathways. Many of these known formulations limit their water content to at most 10% (w / w).

[0076] The use of aprotic polar solvents in preparing non-aqueous therapeutic formulations to inhibit many common degradation pathways, particularly those involving water, can significantly improve the stability of solubilized or dissolved therapeutic molecules. However, problems remain with the compositions and methods disclosed in the art. In particular, direct dissolution of therapeutic molecules in aprotic polar solvents is not an appropriate approach for preparing stable compositions of most therapeutic molecules. When various therapeutic agents are directly dissolved in DMSO, for example, glucagon at a concentration of 5 mg / mL can form insoluble aggregates within one day of storage at room temperature. For a composition containing only glucagon and DMSO, 5 mg / mL corresponds to approximately 0.45% (w / w) of the peptide compound, indicating that even at relatively low concentrations, direct dissolution in an aprotic polar solvent system alone cannot prevent physical aggregation and / or gelation of therapeutic molecules. Furthermore, therapeutic molecules that may not form insoluble aggregates in aprotic polar solvent systems may nevertheless be susceptible to chemical degradation when solubilized directly in aprotic polar solvent systems.

[0077] Without wishing to be bound by theory, it is believed that therapeutic molecules may require a specific ionization profile to exhibit enhanced or optimal stability and solubility when formulated in an aprotic polar solvent system. The ionization profile is the charge state acquired through the protonation and / or deprotonation of the ionogenic groups of a therapeutic molecule. For example, protonation of ionogenic amino acid residues (e.g., arginine, lysine, aspartic acid, glutamic acid) constituting a therapeutic peptide can impart an overall positive charge to the molecule in solution. Alternatively, deprotonation of ionogenic amino acid residues can impart an overall negative charge to the molecule in solution. In the non-limiting examples used herein, protonated (i.e., positively charged) molecules are described, but deprotonation of ionogenic amino acid residues in a therapeutic peptide molecule is also considered within the scope of the present invention. The relatively long-range electrostatic repulsion between positively charged peptide molecules can inhibit short-range hydrophobic interactions that can lead to physical aggregation and / or gelation. Therefore, in the absence of sufficient protonation (i.e., an optimal or beneficial ionization profile), therapeutic molecules dissolved in aprotic polar solvent systems are physically unstable and may form soluble and / or insoluble aggregates. Therefore, it may be necessary to include at least one excipient at a sufficient concentration to function as an ionization-stabilizing excipient that can impart an ionization profile for improved physical and / or chemical stability to the active agent in the aprotic polar solvent system. The appropriate concentration of the ionization-stabilizing excipient added to the solution depends on various factors, including, but not limited to, the chemical structure of the ionization-stabilizing excipient, the chemical structure of the active agent, the concentration of the drug, the solvent system used, the presence of cosolvents, and the presence and respective concentrations of additional excipients or formulation components.

[0078] Certain compositions and methods are designed to establish optimal ionization profiles for therapeutic molecules before they are solubilized in an aprotic polar solvent system. For example, peptide powder from a supplier / manufacturer is first dissolved in a buffered aqueous solution, and the pH of the buffered aqueous peptide solution is set to that for optimal stability and solubility of the individual peptide. The peptide is then dried from the aqueous solution (e.g., via lyophilization or spray drying) to form a powder, so that the ionization profile of the peptide molecules in the powder can be approximately equivalent to that of the peptide molecules in the aqueous solution before drying. When the peptide powder is then solubilized in an aprotic polar solvent system, the ionization profile of the peptide molecules can be approximately equivalent to that of the peptide molecules in the powder. Thus, the ionization profile of the peptide molecules in the aprotic polar solvent system is approximately equivalent to that of the peptide molecules in the buffered aqueous solution.

[0079] The need to dry therapeutic molecules from buffered aqueous solutions to optimize the molecule's ionization profile and provide pH memory before solubilizing them in aprotic polar solvents often imposes significant additional costs, both time and money, on the pharmaceutical manufacturing process. In particular, the drying process is known to impose various burdens on therapeutic molecules, and additional excipients (e.g., cryoprotectants such as trehalose and sucrose, and / or surfactants such as polysorbate 80) must be included in the aqueous solution in amounts sufficient to protect the therapeutic molecule, thereby increasing the cost and complexity of the formulation. Furthermore, drying processes (e.g., spray drying, freeze drying) often must be optimized for a given therapeutic molecule both during initial research and development when the process is first developed, at a research scale, and then during manufacturing when the process is scaled up and transferred to equipment and facilities capable of producing commercial-scale batches. As a result, the combination of initial development and optimization of a drying process for a given therapeutic molecule can be very expensive, combined with the time and costs associated with both transferring the method and incorporating additional steps in the manufacturing process. Without wishing to be bound by theory, it is believed that by providing at least one ionization-stabilizing excipient in a sufficient amount to achieve an appropriate or optimal ionization profile of a therapeutic molecule, electrostatic repulsion between therapeutic molecules of the same charge polarity (i.e., negatively or positively charged) can be sufficient in magnitude to prevent physical degradation (e.g., through short-range hydrophobic interactions between molecules that result in aggregation). This is particularly important for molecules that exhibit a tendency to aggregate in solution, especially when the concentration of the molecule in solution becomes high. Furthermore, by controlling and optimizing the degree of ionization (i.e., protonation or deprotonation) of a therapeutic agent, chemical degradation can be minimized, for example, because excessive protonation can promote chemical destabilization through decomposition reactions, such as oxidation (e.g., oxidation of methionine residues) and fragmentation (e.g., cleavage of the peptide backbone).Thus, for some therapeutic molecules, an optimal or beneficial ionization profile may be achieved through protonation or deprotonation so that physical and / or chemical decomposition reactions are minimized. For therapeutic peptides, the degree of ionization (i.e., protonation or deprotonation) required for stabilization, and therefore the amount of ionization-stabilizing excipient required in solution, may depend, among other things, on its primary structure (i.e., amino acid sequence) and the concentration of the peptide in solution.

[0080] Each molecule functioning as an ionization-stabilizing excipient may exhibit a certain tendency to donate or accept protons to or from the therapeutic molecule and / or additional drug substance / powdered components (e.g., salts, counterions, buffer molecules, etc.) within a given solvent system; the tendency to donate a proton may be expressed as the molecule's relative acidic strength, and the tendency to accept a proton may be expressed as the molecule's relative basic strength. As a non-limiting example, for a fixed concentration of proton-donating molecules (and, for simplicity, assuming only monoprotic molecules in this example), molecules with higher acidic strength may protonate the therapeutic molecule to a greater extent than weaker acids. Thus, the concentration of a given proton-donating molecule (ionization-stabilizing excipient) required to achieve a suitable or optimal ionization profile for a therapeutic molecule may be inversely proportional to its acidic strength. These and other non-limiting aspects of the invention are discussed herein.

[0081] The storage-stable SR formulations of the present invention also contain at least one sustained-release modifier, which is a compound that imparts sustained-release (SR) properties to the therapeutic compound incorporated therein. "Sustained-release" means that the therapeutic agent contained in the formulation exhibits delayed or prolonged release kinetics in an aqueous environment, e.g., in the body of an animal (including a human) administered the SR formulation, compared to an immediate-release, non-SR formulation of the same therapeutic compound that does not contain at least one sustained-release modifier. Examples of sustained-release modifiers suitable for use in accordance with this aspect of the present invention include those that are cation-donating compounds (or cation-containing sources), particularly those that are divalent cation-donating (or divalent cation-containing sources). Suitable such compounds include salts of certain metals, including divalent salts of zinc, e.g., zinc sulfate, zinc chloride, and zinc acetate; divalent salts of magnesium; divalent salts of manganese; divalent salts of calcium; divalent salts of iron; divalent salts of copper; and divalent salts of aluminum. Other suitable divalent salt compounds useful as sustained-release modifiers in accordance with this aspect of the present invention are known in the art and will be familiar to those skilled in the art. When used as sustained-release modifiers in the manufacture of the storage-stable SR formulations of the invention, such divalent cation compounds are included in the formulations at a ratio of salt to therapeutic compound of at least 1:1, suitably 1:1, 2:1, 4:1, 5:1, 8:1, 10:1, 12:1, 15:1, 16:1, 20:1 or higher. As a non-limiting example, a suitable storage-stable SR glucagon formulation of the invention contains a zinc salt (e.g., zinc sulfate, zinc chloride, or zinc acetate) at a zinc:glucagon ratio of 1:1, 2:1, 4:1, 8:1, or 16:1. Other suitable sustained-release modifiers include one or more polymers, including, but not limited to, poly(D,L-lactic-co-glycolic acid) ("PLGA"), such as those available from Evonik (Parsippany, NJ), including Resomer® RG502 (ester-terminated PLGA) and Resomer RG502H (acid-terminated PLGA), poly(ethylene glycol) ("PEG"), and the like.Suitable SR and long-acting ("LA") formulations of peptides can be prepared using one or more PLGAs in various concentrations in the formulations described herein, particularly about 25% to about 50%, about 25% to about 45%, about 25% to about 40%, about 25% to about 35%, and about 25% to about 30%.

[0082] In certain aspects, the aprotic polar solvent can be deoxygenated before preparation of the formulation. Many different techniques can be used in the context of the present invention to deoxygenate or remove oxygen from the aprotic polar solvent (e.g., degassing or deoxygenation). For example, it is contemplated that deoxygenation can remove oxygen dissolved in the liquid aprotic polar solvent by the liquid alone, by the liquid and other solute molecules (e.g., micelles, cyclodextrins, etc.), or by other solute molecules alone, but is not limited thereto. Non-limiting examples of deoxygenation techniques include placing the aprotic polar solvent under reduced pressure and / or heating the liquid to reduce the solubility of dissolved gases, fractional distillation, membrane degassing, displacement with an inert gas, use of a reducing agent, freeze-degass-thaw cycles, or long-term storage in an airlocked container. In one embodiment, the aprotic polar solvent is deoxygenated by vacuum degassing. In another embodiment, the aprotic polar solvent is deoxygenated using a degassing device. In one example, the degasser is a tray-type or cascade-type degasser. In another example, the degasser is a spray-type degasser. In yet another embodiment, the aprotic polar solvent is deoxygenated using a gas-liquid separation membrane. In one example, the aprotic polar solvent is degassed using a gas-liquid separation membrane and reduced pressure. In one embodiment, a non-oxygen gas (e.g., N2) is bubbled through the liquid to replace or reduce oxygen in the aprotic polar solvent. In one example, the gas bubbled through the aprotic polar solvent is argon, helium, nitrogen, an inert gas, and / or hydrogen gas, preferably nitrogen gas. In another example, the gas is bubbled through the aprotic polar solvent using a gas strip column. In yet another embodiment, the aprotic polar solvent is deoxygenated using one or more reducing agents. Non-limiting examples of reducing agents include ammonium sulfite, hydrogen gas, activated deoxidizing metals, copper, tin, cadmium, Wood's metal alloy (50% bismuth, 25% lead, 12.5% ​​tin, and 12.5% ​​cadmium), etc. In yet another embodiment, the aprotic polar solvent is degassed by freeze-degas-thaw cycles (e.g., at least 1, 2, 3, or more cycles can be used).In one example, the freeze-degass-thaw cycle involves freezing the aprotic polar solvent under liquid nitrogen, applying a vacuum, and then thawing the solvent in warm water. In one embodiment, the aprotic polar solvent is deoxygenated by long-term storage in a steel, glass, or wooden container. In another embodiment, the aprotic polar solvent is sonicated, ultrasonicated, or agitated during deoxygenation.

[0083] Once treated or deoxygenated, the aprotic polar solvent may have less than 0.1 mM dissolved oxygen, preferably less than 0.05 mM dissolved oxygen. Methods known to those skilled in the art may be used to determine the amount of dissolved oxygen in any given aprotic polar solvent (e.g., a dissolved oxygen meter or probe device, such as the dissolved oxygen probe commercially available from Vernier (Beaverton, Oregon, USA) may be used).

[0084] In certain aspects, the formulations disclosed herein can be prepared and / or sealed under an inert gas atmosphere. A common method involves backfilling a primary container sealing system (e.g., a vial) to provide a headspace of inert gas (e.g., nitrogen, argon). A secondary container sealing system (e.g., a sealed foil pouch) can also be sealed under an inert gas environment.

[0085] I. Formulations The formulations of the present invention comprise a therapeutic agent present in an aprotic polar solvent system that includes at least one ionization-stabilizing excipient and at least one sustained-release modifier that is compatible with the container and / or fluid flow path, and the therapeutic agent can be dissolved (e.g., completely or partially solubilized) or suspended (completely or partially) in the aprotic polar solvent system.

[0086] In some embodiments, the therapeutic agent is present in a "neat" aprotic polar solvent, i.e., without a co-solvent, or, if a co-solvent is present, without a co-solvent other than water. In other embodiments, the therapeutic agent is present in a solvent system (i.e., an aprotic polar solvent system) that is a mixture of two or more aprotic polar solvents and has a moisture content or water content greater than 10% v / v. An example is a 75 / 25 (% v / v) mixture of DMSO and NMP with a total water content greater than 10% (v / v). However, in some embodiments, a co-solvent may be used, and one or more aprotic polar solvents are mixed with the co-solvent. Non-limiting examples of co-solvents include (explicitly excluding water) ethanol, propylene glycol (PG), glycerol, and mixtures thereof. The co-solvent may be present in the formulation in an amount ranging from about 0.1% (w / v) to about 50% (w / v), e.g., about 0.1%, about 0.5%, about 1%, about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, or about 40% (w / v). In some embodiments, the co-solvent is present in the formulation in an amount ranging from about 10% (w / v) to about 50% (w / v), about 10% (w / v) to about 40% (w / v), about 10% (w / v) to about 30% (w / v), about 10% (w / v) to about 25% (w / v), about 15% (w / v) to about 50% (w / v), about 15% (w / v) to about 40% (w / v), about 15% (w / v) to about 30% (w / v), or about 15% (w / v) to about 25% (w / v).

[0087] Furthermore, the formulations of the present invention may contain one or more other excipients in addition to at least one ionizable stabilizing excipient and at least one sustained-release modifier. In some embodiments, the other excipients are selected from sugars, salts, starches, sugar alcohols, antioxidants, chelating agents, and preservatives. Examples of suitable sugar excipients include, but are not limited to, trehalose, glucose, sucrose, etc. Examples of starches suitable as stabilizing excipients include, but are not limited to, hydroxyethyl starch (HES). Examples of sugar alcohols (also referred to as polyols) suitable as stabilizing excipients include, but are not limited to, mannitol and sorbitol. Examples of suitable antioxidants include, but are not limited to, ascorbic acid, cysteine, methionine, monothioglycerol, sodium thiosulfate, sulfite, BHT, BHA, ascorbyl palmitate, propyl gallate, N-acetyl-L-cysteine ​​(NAC), and vitamin E. Examples of suitable chelating agents include, but are not limited to, EDTA, EDTA disodium salt (edetate disodium), tartaric acid and its salts, glycerin, and citric acid and its salts. Examples of suitable inorganic salts include, but are not limited to, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, calcium sulfate, magnesium sulfate, zinc sulfate, and zinc acetate. Examples of suitable preservatives include, but are not limited to, benzyl alcohol, methylparaben, metacresol, propylparaben, and mixtures thereof. Additional formulation components include local anesthetics, such as lidocaine or procaine.In some embodiments, the additional stabilizing excipient is present in an amount of from about 0.01% (w / v) to about 60% (w / v), from about 1% (w / v) to about 50% (w / v), from about 1% (w / v) to about 40% (w / v), from about 1% (w / v) to about 30% (w / v), from about 1% (w / v) to about 20% (w / v), from about 5% (w / v) to about 60% (w / v), from about 5% (w / v) to about 50% (w / v), from about 5% (w / v) to about 40% (w / v), from about 5% (w / v) to about 30% (w / v), from about 5% (w / v) to about 20% (w / v), from about 10% (w / v) to about 60% (w / v), from about 10% (w / v) to about 50% (w / v), or about 10% (w / v). (w / v) to about 40% (w / v), about 10% (w / v) to about 30% (w / v), or about 10% (w / v) to about 20% (w / v). In some embodiments, the additional stabilizing excipient is present in the formulation in an amount of about, at most, or at least 0.01, 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60% (w / v).

[0088] II. Therapeutic Agents Therapeutic agents in the context of the present invention include peptide or protein compounds, small molecule drugs, and their pharmaceutically acceptable analogs and / or salts. Those skilled in the art will know which therapeutic agents are suitable for treating a particular disease or condition, and will be able to administer an effective amount of the therapeutic agent in the formulations described herein to treat the disease or condition.

[0089] Non-limiting examples of peptides and proteins (and salts thereof) that may be used in the context of the present invention include, but are not limited to, glucagon, pramlintide, insulin, leuprolide, luteinizing hormone-releasing hormone (LHRH) agonists, adrenocorticotropic hormone (ACTH), leuprolide, hirudin, parathyroid hormone (PTH), amylin, angiotensin(1-7), botulinum toxin, hematide, amyloid peptides, gastric inhibitory peptides, antibodies (which may be monoclonal or polyclonal) or fragments thereof, immunogenic peptides (e.g., peptides or peptide complexes derived from viruses, bacteria, or prokaryotic or eukaryotic organisms or cells thereof), insulin-like growth factors, growth hormone-releasing factors, antibacterial factors, glatiramer, glucagon-like peptide-1 (GLP-1), GLP-1 agonists, exenatide, analogs thereof, amylin analogs (pramlintide), and mixtures thereof. In some preferred aspects, the therapeutic agent is glucagon, insulin, and / or pramlintide. Further suitable examples of such peptides, proteins, peptide conjugates, and derivatives thereof that can be advantageously used in the compositions and methods of the present invention will be known to those of skill in the art based on the information provided herein and information readily available in the art.

[0090] Non-limiting examples of small molecule drugs (and salts thereof) that may be used in the context of the present invention include epinephrine, benzodiazepines, levothyroxine, catecholamines, "triptans," sumatriptan, novantrone, chemotherapeutic small molecules (e.g., mitoxantrone), corticosteroid small molecules (e.g., methylprednisolone, betamethasone dipropionate), immunosuppressive small molecules (e.g., azathioprine, cladribine, cyclophosphamide monohydrate, methotrexate), anti-inflammatory small molecules (e.g., salicylic acid, acetylsalicylic acid, lisofylline, diflunisal, choline magnesium trisalicylate, salicylate, benorylate, flufenamic acid, mefenamic acid, meclofenamic acid, triflumic acid,acid), diclofenac, fenclofenac, alclofenac, fentiazac, ibuprofen, flurbiprofen, ketoprofen, naproxen, fenoprofen, fenbufen, suprofen, indoprofen, tiaprofenic acid, benoxaprofen, pirprofen, tolmetin, zomepirac, clopinac, indomethacin, sulindac, phenylbutazone, oxyphenbutazone, azapropazone, feprazone, piroxicam, isoxicam), neurological disorders small molecules used to treat cancer (e.g., cimetidine, ranitidine, famotidine, nizatidine, tacrine, metrifonate, rivastigmine, selegiline, imipramine, fluoxetine, olanzapine, sertindole, risperidone, valproate semisodium, gabapentin, carbamazepine, topiramate, phenytoin), small molecules used to treat cancer (e.g., vincristine, vinblastine, paclitaxel, docetaxel, cisplatin, irinotecan, topotecan, phenytoin), statins (e.g., atorvastatin, amlodipine, rosuvastatin, sitagliptin, simvastatin, fluvastatin, pitavastatin, lovastatin, pravastatin, simvastatin) and other taxane derivatives, small molecules used to treat tuberculosis (e.g., rifampicin), small molecule antifungals (e.g., fluconazole), small molecule anxiolytics and small molecule anticonvulsants (e.g., lorazepam), small molecule anticoli Examples of suitable antihistamines include, but are not limited to, agonists (e.g., atropine), small molecule beta-agonists (e.g., albuterol sulfate), small molecule mast cell stabilizers and small molecule agents used to treat allergies (e.g., cromolyn sodium), small molecule anesthetics and small molecule antiarrhythmics (e.g., lidocaine), small molecule antibiotics (e.g., tobramycin, ciprofloxacin), small molecule antimigraine agents (e.g., sumatriptan), and small molecule antihistamines (e.g., diphenhydramine). In a preferred embodiment, the small molecule is epinephrine.

[0091] Therapeutic agents of the present invention can be administered intradermally for the prevention, diagnosis, mitigation, treatment, or cure of disease. Examples of proteins and proteinaceous compounds that can be formulated in accordance with the present invention and used in delivery systems in accordance with the present invention include proteins that have biological activity or can be used to treat disease or other pathological conditions.

[0092] Each of the above peptides, proteins, and small molecule drugs is well known and commercially available from various manufacturers and suppliers. Furthermore, the amount of peptide, protein, or small molecule drug in a dosage formulation may vary depending on currently accepted amounts, the needs of the subject / patient (e.g., age, health, weight, nature and severity of symptoms), etc., and such amounts can be easily determined by those skilled in the art of pharmacy and pharmacology based on readily available information.

[0093] Therapeutic agents provided by the manufacturer or commercial source are typically provided as powders for dissolution in the formulations described herein. Many known techniques can be used to form powdered agents for dissolution.

[0094] Any suitable dose of the peptide or peptides can be formulated in the stable formulations of the present invention. Generally, the peptide (or each peptide, in embodiments comprising two or more peptides) is present in the formulation in an amount ranging from about 0.1 mg / mL up to the solubility limit of the peptide or peptides. In certain such embodiments, the dose is from about 0.1 mg / mL to about 500 mg / mL, or up to about 200 mg / mL, about 250 mg / mL, about 300 mg / mL, about 350 mg / mL, about 400 mg / mL, about 450 mg / mL, or about 500 mg / mL. In some embodiments, the peptide is present in the formulation in an amount ranging from about 2 mg / mL to about 60 mg / mL. In other embodiments, the peptide is present in the formulation in an amount ranging from about 3 mg / mL to about 50 mg / mL. In still other embodiments, the peptide is present in the formulation in an amount ranging from about 5 mg / mL to about 15 mg / mL. In still other embodiments, the peptide is present in the formulation in an amount ranging from about 0.1 mg / mL to about 10 mg / mL (e.g., about 0.5 mg / mL, about 1 mg / mL, about 2 mg / mL, about 2.5 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 7.5 mg / mL, or about 10 mg / mL). In still other embodiments, the peptide is present in the formulation in an amount ranging from about 1 mg / mL to about 50 mg / mL. Again, it will be readily apparent to one of skill in the art based on the information provided herein and readily available in the relevant art that the dose of the peptide can vary depending on the peptide used and the disease, disorder, or condition being treated.

[0095] In some embodiments, the formulations of the present invention further comprise an antioxidant. In other embodiments, the formulations further comprise a chelating agent. In still other embodiments, the formulations of the present invention further comprise a preservative, a sugar (e.g., a monosaccharide, disaccharide, or polysaccharide, e.g., trehalose dihydrate), a sugar alcohol (e.g., mannitol, xylitol, or erythritol), a polyol, a surfactant, and / or a salt.

[0096] III. Treatment method In another aspect, the present invention provides methods of treating or preventing a disease, condition, or disorder by administering to a subject a therapeutic agent in a stable formulation described herein in an amount effective to treat, alleviate, ameliorate, or prevent the disease, condition, or disorder.

[0097] In some embodiments, the therapeutic methods of the present invention comprise treating hypoglycemia by administering to a subject with hypoglycemia a therapeutic agent for hypoglycemia in a storage-stable SR formulation described herein in an amount effective to treat hypoglycemia. In some embodiments, the subject is administered a storage-stable SR formulation comprising glucagon in a manner that results in release of glucagon from the administration site into the animal's bloodstream or tissues over a prolonged period of time (i.e., "sustained release") compared to non-SR (or "immediate release") formulations comprising glucagon. In certain aspects, the hypoglycemia can be due to diabetes (including type 1 or type 2 diabetes, exercise-induced or exercise-related diabetes, post-obesity diabetes, gestational diabetes, nocturnal diabetes, etc.) or non-diabetic-related diseases, conditions, and disorders.

[0098] As reported by the American Diabetes Association and the Endocrine Society workgroup on hypoglycemia (Seaquist, et al, (2013), Diabetes Care, Vol 36, pages 1384-1395), a single plasma glucose concentration threshold that defines hypoglycemia in diabetes has not typically been specified because the glycemic threshold for hypoglycemic symptoms shifts (among other responses) to lower plasma glucose concentrations after recent preceding hypoglycemia and to higher plasma glucose concentrations in patients whose diabetes is poorly controlled and who do not experience frequent hypoglycemia.

[0099] However, warning levels can be defined that draw the attention of both patients and caregivers to the potential harm associated with hypoglycemia. Patients at risk for hypoglycemia (i.e., those treated with sulfonylureas, glinides, and insulin) should be warned of the possibility of developing hypoglycemia when their self-monitored plasma glucose—or continuous glucose monitored subcutaneous glucose—concentrations are ≤ 70 mg / dL (≤ 3.9 mmol / L). Because this is higher than the glycemic threshold for symptoms in both nondiabetic and well-controlled individuals, it usually allows time to prevent a clinical hypoglycemic episode and provides some margin for the limited accuracy of monitoring devices at low glucose levels.

[0100] A severe hypoglycemic event is one that requires the assistance of another person to actively administer carbohydrates, glucagon, or other corrective measures. Although plasma glucose levels may not be available during the event, neurological recovery after return of plasma glucose to normal is considered sufficient evidence that the event was induced by a low plasma glucose level. Typically, these events begin to occur at plasma glucose levels of ≤50 mg / dL (≤2.8 mmol / L). A documented symptomatic hypoglycemia is an event accompanied by typical symptoms of hypoglycemia and a measured plasma glucose level of ≤70 mg / dL (≤3.9 mmol / L). An asymptomatic hypoglycemia is an event not accompanied by typical symptoms of hypoglycemia, but accompanied by a measured plasma glucose level of ≤70 mg / dL (≤3.9 mmol / L). A probable symptomatic hypoglycemia is an event in which the plasma glucose measurement is not accompanied by symptoms typical of hypoglycemia, but is thought to be caused by a measured plasma glucose concentration of ≦70 mg / dL (≦3.9 mmol / L). A pseudohypoglycemia is an event in which a person with diabetes reports any of the typical symptoms of hypoglycemia and the measured plasma glucose concentration is >70 mg / dL (>3.9 mmol / L) but is approaching that level.

[0101] Additionally, hypoglycemia-associated autonomic failure (HAAF) is included among the indications that can be treated with the disclosed invention. As described in Philip E. Cryer, *Perspectives in Diabetes, Mechanisms of Hypoglycemia-Associated Autonomic Failure and Its Component Syndromes in Diabetes*, Diabetes, Vol. 54, pp. 3592-3601 (2005), "Recent preceding iatrogenic hypoglycemia leads to both defective glucose counterregulation (by reducing the epinephrine response to a certain level of subsequent hypoglycemia in the absence of insulin reduction and glucagon increase) and hypoglycemic unawareness (by reducing the sympathoadrenomedullary response to a certain level of subsequent hypoglycemia and the resulting neurogenic symptom response), thus creating a vicious cycle of hypoglycemia." HAAF affects individuals with type 1 and advanced type 2 diabetes. Furthermore, the disclosed invention can also treat hypoglycemia in patients after pancreatic islet cell transplantation.

[0102] The formulations of the present invention can also be used to treat hyperinsulinemic hypoglycemia, which broadly refers to the condition and effects of low blood glucose levels caused by excess insulin. The most common type of severe but typically transient hyperinsulinemic hypoglycemia is caused by the administration of exogenous insulin in type 1 diabetic patients. This type of hypoglycemia can be defined as iatrogenic hypoglycemia and is a limiting factor in the glycemic control of type 1 and type 2 diabetes. Nocturnal hypoglycemia (nocturnal hypoglycemia) is a common type of iatrogenic hypoglycemia that occurs in patients taking exogenous insulin. However, hyperinsulinemic hypoglycemia can also be caused by endogenous insulin, for example, in congenital hyperinsulinemia, insulinoma (insulin-secreting tumor), exercise-induced hypoglycemia, and reactive hypoglycemia. Reactive hypoglycemia is a non-diabetic form of hypoglycemia caused by low blood glucose levels that occur after a meal (typically within 4 hours after a meal). Reactive hypoglycemia can also be referred to as postprandial hypoglycemia. Symptoms and signs of reactive hypoglycemia may include hunger, weakness, trembling, drowsiness, sweating, confusion, and anxiety. Gastric surgery (e.g., bariatric surgery) is one possible contributing factor, as food may pass too quickly into the small intestine after surgery (post-bariatric hypoglycemia (PBH)). Additional contributing factors include enzyme deficiencies that make it difficult for the body to break down food, or increased sensitivity to the hormone epinephrine.

[0103] In some embodiments, the disease, condition, or disorder treated with the stable formulation of the present invention is a diabetic condition.Examples of diabetic conditions include, but are not limited to, type 1 diabetes, type 2 diabetes, gestational diabetes, prediabetes, hyperglycemia, hypoglycemia, and metabolic syndrome.In some embodiments, the disease, condition, or disorder is hypoglycemia, including, but not limited to, diabetes-related hypoglycemia, exercise-induced hypoglycemia, and post-bariatric surgery hypoglycemia, or other types of hypoglycemia described herein and known to those skilled in the art.In some embodiments, the disease, condition, or disorder is diabetes.

[0104] In some embodiments, the therapeutic methods of the present invention comprise treating diabetes by administering to a subject with diabetes an amount of a therapeutic agent in a stable formulation described herein effective to treat diabetes. In some embodiments, the subject is administered a stable formulation comprising insulin. In some embodiments, the subject is administered a stable formulation comprising pramlintide. In some embodiments, the subject is administered a stable formulation comprising insulin and pramlintide. In some embodiments, the subject is administered a stable formulation comprising exenatide. In some embodiments, the subject is administered a stable formulation comprising glucagon and exenatide.

[0105] In certain aspects, epinephrine can be administered to subjects at risk of or suspected of anaphylaxis.Epinephrine is designated as an emergency treatment for type I allergic reactions, which can be caused by multiple causes, including but not limited to food, drug and / or other allergens, allergen immunotherapy, diagnostic test materials, insect stings and bites, and sudden or exercise-induced anaphylaxis.

[0106] Dosages of the peptide or small molecule drugs described herein for treating a disease, condition, or disorder (e.g., a diabetic condition, hypoglycemia, or anaphylaxis) follow dosage and scheduling strategies practiced by those skilled in the art. General guidelines for appropriate dosages of all pharmacological agents used in the methods of the invention are provided in Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 11th Edition, 2006, supra, and in the Physicians' Desk Reference (PDR), e.g., its 65th (2011) or 66th (2011) edition, PDR Network, LLC, each of which is incorporated herein by reference. Appropriate dosages of peptide drugs for treating a disease, condition, or disorder described herein may vary according to various factors, including the formulation of the composition, the patient's response, the severity of the condition, the subject's weight, and the judgment of the prescribing physician. Effective dosages of the described formulations deliver a medically effective amount of the peptide drug. Doses may be increased or decreased over time as needed by the individual patient or as determined by a physician.

[0107] Determining effective amounts or doses is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein. Generally, formulations that deliver these doses may contain one, two, three, four, or more small molecules, peptides, or peptide analogs (collectively "peptides" unless peptide analogs are expressly excluded), with each peptide present in the formulation at a concentration from about 0.1 mg / mL up to the solubility limit of that peptide. This concentration is preferably about 1 mg / mL to about 100 mg / mL. In certain aspects, the concentration is about 1 mg / mL, about 2 mg / mL, about 2.5 mg / mL, about 3 mg / mL, about 4 mg / mL, about 5 mg / mL, about 7.5 mg / mL, about 10 mg / mL, about 15 mg / mL, about 20 mg / mL, about 25 mg / mL, about 30 mg / mL, about 35 mg / mL, about 40 mg / mL, about 45 mg / mL, about 50 mg / mL, about 55 mg / mL, about 60 mg / mL, about 65 mg / mL, about 70 mg / mL, about 75 mg / mL, about 80 mg / mL, about 85 mg / mL, about 90 mg / mL, about 95 mg / mL, or about 100 mg / mL. Concentrations of small molecules are known to those skilled in the art and can be established and implemented using the disclosure provided herein, for example, at doses of 0.01 mg / ml to 500 mg / ml, or about 1, 2, 2.5, 3, 4, 5, 10, 25, 50, 75, 100, 200, 500 to about 1000 mg, including all values ​​and ranges therebetween.

[0108] The formulations of the present invention can be used for parenteral administration, including but not limited to subcutaneous, intradermal, intramuscular, intranasal, oral, transdermal, or intravenous administration (e.g., by injection or infusion).In some embodiments, the formulation is administered subcutaneously.The formulation can also be delivered transdermally, for example, by topically applying the composition to the skin (e.g., by spreading the composition on the skin or by loading the composition into a skin patch and applying the skin patch to the skin).

[0109] The formulations of the present disclosure can be administered by infusion or injection using any suitable device. For example, the formulations of the present disclosure can be contained in a syringe (e.g., a pre-filled syringe), a pen injection device, an automatic injection device, or a pump device. In some embodiments, the injection device is a multi-dose injection pump device or a multi-dose automatic injection device. The formulation is present in the device in such a manner that it can easily flow out of the needle to deliver the peptide drug when the injection device, e.g., an automatic injector, is activated. Suitable pen / automatic injection devices include, but are not limited to, pen / automatic injection devices manufactured by Becton-Dickenson, Swedish Healthcare Limited (SHL Group), YpsoMed Ag, etc. Suitable pump devices include, but are not limited to, pump devices manufactured by Tandem Diabetes Care, Inc., Delsys Pharmaceuticals, etc.

[0110] In some embodiments, the formulations of the invention are provided ready to administer in vials, cartridges, or pre-filled syringes.

[0111] In some embodiments, the stable formulation is used to formulate a medicament for treating hypoglycemia. In some embodiments, the stable formulation comprises glucagon or a salt thereof (e.g., glucagon acetate). In some embodiments, the stable formulation comprises glucagon and exenatide.

[0112] In some embodiments, the stable formulation is used to formulate a medicament for the treatment of diabetes. In some embodiments, the stable formulation comprises insulin. In some embodiments, the stable formulation comprises exenatide. In some embodiments, the stable formulation comprises pramlintide. In some embodiments, the stable formulation comprises insulin and pramlintide.

[0113] In further embodiments, the formulations provided by the present invention can be used in certain diagnostic procedures. In certain such embodiments, the glucagon-containing formulations of the present invention can be administered to a mammal, such as a human or vertebrate, prior to, adjunct to, as part of, or in combination with one or more diagnostic procedures, thereby providing a method of diagnosing a disease or disorder in a patient suffering from or susceptible to the disease or disorder. Non-limiting examples of such diagnostic procedures in which the glucagon-containing formulations of the present invention may be suitably used include methods of diagnosing Alzheimer's disease (see U.S. Pat. No. 4,727,041, which is incorporated herein by reference in its entirety) and growth hormone deficiency (see U.S. Pat. No. 5,065,747; see also Boguszewski, CL, Endocrine 57: 361-363 (2017), and Yuen, KCJ, ISRN Endocrinology, vol. 211, Article ID 608056, pp. 1-6 (2011), doi:10.5402 / 2011 / 608056; the disclosures of all of which are incorporated herein by reference in their entirety). Further examples of such uses are in certain radiological diagnostic procedures, particularly those used in the diagnosis of gastrointestinal disease conditions (non-limiting examples of which include intestinal obstruction, appendicitis, Barrett's esophagus, celiac disease, cancer, cirrhosis of the liver, Crohn's disease, diverticulitis, diverticulosis, ulcers, gallstones, gastric prolapse, gastritis, gastroesophageal reflux disease, hepatitis (A / B / C), hiatal hernia, inflammatory bowel disorder, hernia, irritable bowel syndrome, pancreatitis, perianal cleft, ulcerative colitis, etc.), in adult patients. during radiological examinations of the gastrointestinal system to temporarily inhibit the movement of organs and connective tissues of the gastrointestinal tract (see, e.g., the product label for glucagon lyophilized (NDC code 63323-185-03), available at https: / / dailymed.nlm.nih.gov / dailymed / drugInfo.cfm?setid=8c8acad6-44cc-43aa-966b-027e053be8f5); Glucagon in Gastroenterology(See also J. Picazo, ed., Lancaster, England: MTP Press Ltd. (1979), especially Chapters 3-7, pp. 39-120; the disclosure of which is incorporated herein by reference.) In such diagnostic methods, the glucagon-containing formulations of the present invention are administered to a patient suffering from or susceptible to a disorder by any suitable method for introducing such a formulation into the patient's body, such as those described herein, e.g., intravenously at a dose of about 0.2 mg to about 0.75 mg about 1 to 10 minutes before a diagnostic test (e.g., a radiological procedure), or intramuscularly or transdermally at a dose of about 1 mg to about 2 mg about 5 to 15 minutes before a diagnostic test (e.g., a radiological procedure). Other suitable therapeutic and diagnostic methods of use of the formulations of the present invention will be readily known to a physician or pharmacist of ordinary skill based on the disclosure contained herein in light of information available in the art.

[0114] IV. Kits / Containers Kits are also contemplated for use in certain aspects of the present invention. For example, the formulations of the present invention can be included in a kit that can include a container. In one aspect, for example, the formulation can be contained in a container that is ready to be administered to a subject or incorporated into a device configured to administer to a subject without the need to reconstitute or dilute the formulation. That is, the formulation to be administered can be stored in the container and used immediately when needed. The container can be a device. The device can be a syringe (e.g., a pre-filled syringe), a pen injection device, an autoinjector device, a device capable of pumping or administering the formulation (e.g., an automatic or non-automatic external pump (e.g., a patch pump or a pump requiring an external infusion set), an implantable pump), or a perfusion bag. Suitable pen / autoinjector devices include, but are not limited to, pen / autoinjector devices manufactured by Becton-Dickenson, Swedish Healthcare Limited (SHL Group), YpsoMed Ag, etc. Suitable pump devices include, but are not limited to, pump devices manufactured by Tandem Diabetes Care, Inc., Delsys Pharmaceuticals, etc. Suitable infusion sets include, but are not limited to, those manufactured / distributed / sold by Tandem Diabetes Care, Inc., Medtronic, Disetronic, YpsoMed Ag, Unomedical A / S, and others. [Example]

[0115] Some aspects of the present disclosure will be described in more detail by specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way. For example, those skilled in the art will easily recognize various non-critical parameters that can be changed or modified to achieve essentially the same results without undue experimentation.

[0116] Example 1: Preparation of sustained-release glucagon formulations Previous reports on the preparation of sustained-release glucagon formulations were based on the preparation of aqueous zinc-glucagon suspensions and the crystallization of the Zn-glucagon complex; upon rehydration, such Zn-glucagon suspensions exhibited sustained release of glucagon (see Trading, F. et al., Eur. J. Pharmacol. 7:206-210 (1969)). However, such aqueous suspensions of glucagon must be prepared immediately prior to therapeutic use because suspension of glucagon in an aqueous solution results in rapid hydrolysis and inactivation of glucagon, a problem that can be overcome by dissolving glucagon in an aprotic solvent system, such as DMSO, which improves the long-term storage stability of glucagon solutions (see, e.g., U.S. Pat. Nos. 9,339,545 and 10,485,850, the disclosures of which are incorporated herein in their entireties). Therefore, it was desirable to evaluate the ability to prepare sustained-release (SR) formulations of glucagon that exhibit storage stability even in solution.

[0117] In an initial study of the stability of such formulations, glucagon formulations were prepared in glass vials at 5 mg / mL or 10 mg / mL in DMSO and also containing various concentrations of a divalent zinc compound (zinc chloride, zinc acetate, or zinc sulfate) in solution. All formulations also contained the following components: 5.5% (w / v) trehalose dihydrate and 2.9% (w / v) mannitol. The following exemplary formulations were prepared (the "control" is a commercially available non-SR liquid glucagon formulation (GVOKE®; Xeris Pharmaceuticals, Inc., Chicago, IL)):

[0118] Table 1. Exemplary SR Glucagon Formulations TIFF0007828300000001.tif120160

[0119] Divalent zinc compounds were selected based on their compatibility with glucagon formulations and suitability for subcutaneous use. The physiochemical stability of these formulations was analyzed via visual analysis and reverse-phase UHPLC (RP-UPHLC) after storage at various temperatures (-20°C, 5°C, 25°C / 60% relative humidity, or 40°C / 75% relative humidity) in a stability test chamber. After up to 6 months of storage, samples of each formulation were visually examined and photographed for discoloration, gelation, or aggregation of the vial contents. For RP-UPHLC analysis, a gradient method was developed based on 1% trifluoroacetic acid (TFA) and acetonitrile and a Waters ACQUITY UPLC® Peptide CSH C18, 100 mm x 2.1 mm, 1.7 μm, 130 Å column. Detection was performed at 280 nm, the flow rate was 0.55 mL / min, the column temperature was 60°C, and the injection volume was 25 μg of glucagon. The purity of glucagon in each formulation was determined by assessing the area of ​​the main peak (undegraded glucagon) as a percentage of the main peak in the starting material (time zero) for that formulation.

[0120] Figure 1 shows exemplary photographs of two exemplary SR glucagon formulations listed in Table 1 -- Formulation A-1 (Figure 1A) and Formulation A-2 (Figure 1B) -- taken immediately after preparation. As can be seen in Figure 1, no discoloration, gelation, or aggregation was visually observed in the vials for these formulations at storage time T=0. Similar results were obtained for the other formulations listed in Table 1 (data not shown).

[0121] Over storage periods of up to 6 months at various temperatures, some SR formulations performed better than others in terms of storage stability, as assessed visually with respect to discoloration and aggregation / fibrillation. These results are shown in Figures 2-5.

[0122] In samples stored at −20° C. for 6 months (FIG. 2), the following visual results were obtained with respect to discoloration (FIG. 2A) and fibrillation (FIG. 2B).

[0123] TIFF0007828300000002.tif51139

[0124] In samples stored at 5°C for 6 months (Figure 3), the following visual results were obtained with respect to discoloration (Figure 3A) and fibrillation (Figure 3B).

[0125] TIFF0007828300000003.tif75139

[0126] In samples stored at 25°C for 6 months (Figure 4), the following visual results were obtained with respect to discoloration (Figure 4A) and fibrillation (Figure 4B).

[0127] TIFF0007828300000004.tif56139

[0128] In samples stored at 40°C / 75% relative humidity for 6 months (Figure 5), the following visual results were obtained with respect to discoloration (Figure 5A) and fibrillation (Figure 5B).

[0129] TIFF0007828300000005.tif56139

[0130] More sensitive analysis of the stability of some of these formulations via RP-UHPLC (specifically, those stored at 25°C for 6 months; Figure 4) revealed similar results, as shown in Table 2.

[0131] Table 2. Purity of glucagon formulations stored at 25°C for 6 months by RP-UHPLC. TIFF0007828300000006.tif80143

[0132] These studies were extended to 12 months of storage of these same formulation samples stored at 5°C and 25°C. The results are shown in Figure 7. As seen in Figures 7A and 7B, storage of samples at 5°C for up to 12 months resulted in negligible degradation or fibrillation of the formulations, and all formulations exhibited 98-99% purity, even after 12 months of storage, as assessed by RP-UHPLC. Storage of formulation samples at 25°C for 12 months (Figures 7C and 7D) showed that the initial minor degradation seen in the 4:1 glucagon:zinc acetate formulation continued for 6-12 months, until approximately 84% purity was observed in this sample. In contrast, the 8:1 glucagon:zinc acetate and 8:1 glucagon:zinc chloride formulations continued to degrade, but at a much slower rate, retaining approximately 92-94% of their initial purity after 12 months of storage at 25°C.

[0133] In summary, these results indicate that all zinc-containing SR glucagon formulations exhibited long-term room temperature stability for at least 3 months, with formulations containing zinc chloride (B-1, B-2) and zinc sulfate (C-1 and C-2) exhibiting longer-term stability (up to at least 6 months) at 25°C to 40°C compared with the zinc acetate-containing formulations (A-1, A-2), which exhibited slightly less stability when stored at 25°C to 40°C for 6 months. Similar results were observed at longer storage times, with all formulations exhibiting excellent long-term shelf life (at least 12 months) after storage at 5°C and slightly less stability after longer storage (12 months) at 25°C, with the 8:1 glucagon / zinc acetate formulation exhibiting the greatest long-term stability when stored at 25°C. The storage stability of the zinc chloride and zinc sulfate formulations at 25°C to 40°C was similar to that observed with the reference formulation, a commercially available shelf-stable liquid glucagon formulation.

[0134] Example 2: Evaluation of storage-stable SR glucagon formulations in preclinical studies Based on the above results, it was of interest to test the initial pharmacokinetics (PK) of the storage-stable SR glucagon formulation described in Example 1 in a preclinical study in laboratory animals. All jugular-cannulated Sprague-Dawley rats (n=3 / group) were administered the test formulation subcutaneously via needle and syringe into a tented skin area between the shoulder blades. The dose volume was adjusted based on the animal's body weight on the morning of dosing. Storage-stable SR glucagon solution was administered as a 60-250 μL injection at 2 mg / kg to 8 mg / kg. A similar formulation of a commercially available non-SR glucagon rescue product (GVOKE®; Xeris Pharmaceuticals, Chicago, IL) was used as a control. Blood samples were collected from each animal into K2EDTA protease inhibitor P800 blood tubes before dosing and at 0.25, 0.5, 1, 1.5, 2, 4, 6, 12, 24, and 48 hours after dosing. Pharmacokinetic parameters were analyzed in the three treatment groups and controls. Plasma glucagon was assayed via LC-MS at AltaSciences (Laval, Quebec, Canada). Non-compartmental PK analysis was performed in each animal. Cmax and Tmax were calculated from the observed data, and area under the curve (AUC) estimates were calculated using the linear trapezoidal method as follows: TIFF0007828300000007.tif7128 Elimination half-life TIFF0007828300000008.tif5128 was calculated as follows: Exemplary PK results for one of the TIFF0007828300000009.tif39128SR glucagon formulations (A-1) are shown in FIG.

[0135] As can be seen in Figure 6, there was an extension of the elimination half-life of glucagon from approximately 0.3 hours for the non-SR control to at least 6.1 hours for the SR (zinc-containing) glucagon formulation. Furthermore, the SR formulation provided a minimal burst release of glucagon (Cmax = 73 ng / mL) and exhibited a relatively flat and temporally extended release profile compared to the non-SR immediate-release control formulation (Cmax = 214 ng / mL). Thus, the storage-stable SR glucagon formulation of the present invention can maximize the time that blood glucagon levels remain within the therapeutic window after administration, unlike the control, which is a commercially available rescue product intended to rapidly elevate glucagon levels in response to severe hypoglycemic events.

[0136] These pharmacokinetic studies were then extended with additional formulations, including those described in Example 1, to test whether these formulations might be suitable for producing SR glucagon formulations that could be therapeutically effective with administration to a subject only once daily. The formulations were prepared as shown in Table 3.

[0137] Table 3. Zinc-glucagon formulations prepared for animal PK studies TIFF0007828300000010.tif189150

[0138] These formulations were then administered subcutaneously to rats as described elsewhere herein, and plasma glucose levels were assessed over a 12-hour period in treated animals. The results are shown in Figure 8. As seen in Figures 8A and 8B, the control immediate-release GVOKE® (glucagon injection) formulation exhibited the expected kinetics of a higher Cmax and a shorter plasma half-life compared to the SR (zinc-containing) glucagon formulation. Specific PK values ​​for each of these formulations are shown in Table 4.

[0139] Table 4. Pharmacokinetic results of once-daily SR glucagon formulation TIFF0007828300000011.tif93164

[0140] These results demonstrate that it is possible to prepare sustained-release glucagon formulations that provide optimal and therapeutic plasma glucagon concentrations for extended periods of time, even with administration only once daily. In particular, formulations with higher zinc:glucagon ratios exhibited a reduced initial burst release of glucagon (i.e., lower Cmax) and a slower decline in plasma glucagon levels over time. Furthermore, at the indicated zinc:glucagon ratios, administration of higher doses of the formulation or higher concentrations of glucagon in the formulation both resulted in higher plasma glucagon activity (i.e., higher AUC and T 1 / 2 ) resulted.

[0141] Taken together with the results of Example 1, these results demonstrate that it is possible to produce a storage-stable SR glucagon formulation that has not previously been shown or anticipated. Such storage-stable SR glucagon formulations could potentially be used not only in emergency rescue scenarios for patients suffering from acute severe hypoglycemia, but also in non-emergency treatment and prevention approaches to manage blood glucose levels, potentially over a long period of time, for example, before sleep, before exercise, or in situations where the patient may not be aware of a drop in blood glucose. Furthermore, these results demonstrate that it is also possible to prepare glucagon formulations that can be advantageously administered to patients once daily, thereby eliminating the need to use glucagon only in rescue situations and potentially providing better management of a patient's blood glucose levels than is currently available.

[0142] Example 3: Preparation of a once-weekly glucagon formulation Having demonstrated the ability to produce sustained-release (SR) glucagon formulations, it became of interest to the inventors to determine whether the same principles could be applied to the preparation of long-acting ("LA") glucagon formulations, e.g., formulations that could be administered only once a week to patients requiring blood glucose control. Ideally, such a formulation would provide for subcutaneous or intradermal administration, a minimal initial burst release of glucagon, and a nearly linear release of glucagon into the bloodstream over at least one week without the need for further glucagon administration during that period. Such a formulation would be particularly useful, by way of example, for patients with type 2 diabetes, and could offer not only better self-management of blood glucose by these patients, but also the potential for weight loss and improved HbA1c levels in such patients.

[0143] To prepare these formulations, glucagon was formulated with specific polymers that provide sustained release of various peptide therapeutics. In particular, poly-lactide-co-glycolide (PLGA) was investigated as a suitable carrier for preparing such LA glucagon formulations. Two PLGA polymers were tested: RESOMER® RG502 (poly(D,L-lactide-co-glycolide) 50:50, 0.16-0.24 dl / g (MW approximately 7-17 kD)) with ester end groups, and RESOMER® RG502H (poly(D,L-lactide-co-glycolide) 50:50, 0.16-0.24 dl / g (MW approximately 7-17 kD)) with acid end groups, both from Evonik (Parsippany, NJ). Various formulations of glucagon (100 mg / ml) in DMSO were prepared as described in Examples 1 and 2 and diluted with trehalose (5% PLGA was added to the formulations in the presence or absence of DMSO-glucagon (w / v). Samples of each formulation were then stored at -20°C, 5°C, 25°C, and 40°C for 3 months, and the samples were evaluated for storage stability as described in the previous Examples. The results are shown in Figure 9. As observed in the previous Examples, all formulations, including the immediate-release GVOKE® control formulation, showed virtually no degradation over 3 months when stored at -20°C (Figure 9A). In contrast, the immediate-release formulations degraded significantly at 5°C (Figure 9B), 25°C (Figure 9C), and 40°C (Figure 9D), whereas the SR formulations formulated with PLGA showed much better storage stability, and two formulations (containing either ester-terminated PLGA or PLGA and trehalose) showed enhanced long-term storage stability even at 40°C (Figure 9D). These results indicate that the addition of PLGA to the formulation does not decrease the storage stability of the DMSO-glucagon formulations, but rather appears to enhance it.

[0144] The pharmacokinetics of these PLGA-containing formulations were then tested when administered to test animals (male SD rats) using the method described in Example 2 above. As shown in Figure 10, the PLGA-containing formulations produced in these initial studies did not provide the desired pharmacokinetics. Although a lower Cmax was observed in two PLGA-containing formulations, neither of these formulations provided a longer plasma glucagon release, which is the goal of such formulations.

[0145] To optimize formulations and attempt to provide the possibility of producing LA glucagon formulations, in vitro release assays were used to test the release kinetics of test formulations without the need to sacrifice animals during formulation development. In these experiments, test glucagon formulations were introduced into an aqueous release medium (PBS) in a test vessel incubated at 37°C, and samples were taken from this aqueous medium and tested for glucagon concentration over time. The results of one example of such a study are shown in Figure 11. A formulation containing 250 mg / mL glucagon and 40% Resomer® RG502 in acidified DMSO exhibited a relatively high initial burst release of glucagon and a nonlinear release over 7 days (Figure 11A). In contrast, formulations containing 100 mg / mL glucagon and 40% Resomer RG502 or 33% Resomer RG502H exhibited a near-linear release with a low initial burst release of glucagon (Figure 11B), although these formulations exhibited a much longer release period than desired (more than the one month required to release the entire dose of glucagon).

[0146] These initial results were then used to optimize the formulation of glucagon in PLGA in an attempt to obtain a formulation that would provide optimal release characteristics within a reasonable time frame (e.g., 1–2 weeks). Nine formulations were prepared using Resomer RG502 (ester-terminated) PLGA and various concentrations of glucagon and evaluated in the in vitro assay described above. The results of these studies are shown in Figure 12. As can be seen in this figure, formulations containing 250 mg / mL glucagon and either 33% or 40% PLGA, and formulations containing 281 mg / mL glucagon and 36.5% PLGA, exhibited a relatively low initial burst (Cmax) followed by sustained release over time, with complete release of glucagon from the formulation achieved within approximately 10–11 days. These results demonstrate that it is possible to produce LA glucagon formulations characterized by a low initial burst release of glucagon and a prolonged release over time, with complete release of glucagon from the injected formulation into the bloodstream within 2 weeks.

[0147] All of the compositions and / or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of the present disclosure have been described in terms of several embodiments, it will be apparent to those skilled in the art that variations can be applied to the compositions and methods described herein and in the steps or sequence of steps of the methods without departing from the concept, spirit, and scope of the present disclosure. More specifically, it will be apparent that the agents described herein may be substituted with certain agents that are both chemically and physiologically related and still achieve the same or similar results. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope, and concept of the invention as defined by the appended claims.

Claims

1. (a) a therapeutic agent that is a glucagon peptide; (b) at least one ionizable stabilizing excipient that is an inorganic acid; and (c) at least one sustained-release modifier that is a zinc salt; and (d) dimethyl sulfoxide (DMSO), an aprotic polar solvent; 1. A storage stable sustained release therapeutic formulation comprising: the glucagon peptide is present in DMSO at a concentration of 5 mg / mL or 10 mg / mL, the formulation is storage stable at 25°C for at least 6 months, and the formulation, when administered to a patient, results in therapeutic levels of the therapeutic agent in the patient's blood for an extended period of time compared to an immediate release formulation containing the same therapeutic agent; Storage stable sustained release therapeutic formulation.

2. 10. The formulation of claim 1, wherein the inorganic acid is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid.

3. 3. The formulation of claim 1 or 2, wherein the zinc salt is selected from the group consisting of zinc acetate, zinc chloride, and zinc sulfate.

4. 4. The formulation of claim 3, wherein the zinc salt is zinc sulfate.

5. 10. The formulation of claim 1, further comprising at least one polymer suitable for use in preparing a sustained release formulation of the peptide.

6. 6. The formulation of claim 5, wherein the polymer is PLGA.

7. 7. The formulation of claim 6, wherein the PLGA is an ester-terminated PLGA or an acid-terminated PLGA.

8. 8. The formulation of any one of claims 5 to 7, which provides complete release of said peptide from said formulation into the bloodstream of an animal administered said formulation within a period of 7 to 14 days.

9. 10. The formulation of claim 1, wherein the glucagon peptide is present in DMSO at a concentration of 5 mg / mL.

10. 10. The formulation of claim 1, wherein the glucagon peptide is present in DMSO at a concentration of 10 mg / mL.

11. 3. The formulation of claim 2, wherein the inorganic acid is sulfuric acid or hydrochloric acid.

12. 12. The formulation of any one of claims 1 to 11, further comprising trehalose dihydrate.

13. 13. The formulation of claim 12, wherein the trehalose dihydrate is at a concentration of 5.5% (w / v).

14. 14. The formulation of any one of claims 1 to 13, further comprising mannitol.

15. 15. The formulation of claim 14, wherein the mannitol is at a concentration of 2.9% (w / v).

16. 4. The formulation of claim 3, wherein the zinc:glucagon ratio is 1:1, 2:1, 4:1, 8:1, or 16:

1.

17. 17. The formulation of claim 16, wherein the zinc:glucagon ratio is 4:1 or 8:

1.

18. 18. The formulation according to any one of claims 1 to 17 for treating or preventing hypoglycemia.

19. 20. The formulation of claim 18, wherein the formulation is introduced into a patient via parenteral administration.

20. 20. The formulation of claim 19, wherein the parenteral administration is via injection or infusion.

21. 21. The formulation of claim 20, wherein the injection is subcutaneous, intradermal, or intramuscular.

22. 21. The formulation of claim 20, wherein the infusion is intravenous.

23. 21. The formulation of claim 20, wherein the infusion is achieved by pump infusion.

24. 24. The formulation of claim 23, wherein the pump infusion comprises continuous or bolus pump infusion, or a combination thereof.

25. 1. A method for producing a storage-stable sustained-release therapeutic formulation, the method comprising the steps of combining at least one ionizable stabilizing excipient that is an inorganic acid, at least one sustained-release modifier that is a zinc salt, an aprotic polar solvent that is dimethyl sulfoxide (DMSO), and at least one therapeutic agent that is a glucagon peptide at a concentration of 5 mg / mL or 10 mg / mL in DMSO, thereby forming a storage-stable therapeutic formulation that, when administered to a patient, results in the presence of therapeutic levels of the therapeutic agent in the patient's blood for an extended period of time compared to an immediate-release formulation containing the same therapeutic agent.

26. 26. The method of claim 25, wherein the inorganic acid is selected from the group consisting of hydrochloric acid, sulfuric acid, nitric acid, and phosphoric acid.

27. 27. The method of claim 25 or 26, wherein the zinc salt is selected from the group consisting of zinc acetate, zinc chloride, and zinc sulfate.

28. 28. The method of claim 27, wherein the zinc salt is zinc sulfate.

29. 26. The method of claim 25, wherein the ratio of zinc:glucagon is 1:1, 2:1, 4:1, 8:1, or 16:

1.

30. 30. The method of claim 29, wherein the ratio of zinc:glucagon is 4:1, or 8:

1.

31. 20. The formulation of any one of claims 1 to 17 for use in a method of diagnosing a disease or physical disorder in a human patient by introducing an effective amount of the formulation to a patient suffering from or susceptible to the disease or disorder as an adjunct to a diagnostic test, and administering the diagnostic test to the patient.

32. 32. The formulation of claim 31, wherein the patient has or is susceptible to Alzheimer's disease.

33. 32. The formulation of claim 31, wherein the patient has or is susceptible to growth hormone deficiency.

34. 32. The formulation of claim 31, wherein the patient is suffering from or susceptible to a gastrointestinal disorder.

35. 32. The formulation of claim 31, wherein the diagnostic test is a radiological examination of the patient's gastrointestinal tract.

36. 32. The formulation of claim 31, wherein the formulation is introduced into a patient intravenously, intramuscularly, or intradermally.

Images